Date: August 22, 2025

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex
Bandra (East), Mumbai-400051.

Respected Sir/Ma'am

Sub: Submission of Revised Annual Report for Financial Year 2024-25.

Ref: Aristo Bio-Tech and Lifescience Limited (SYMBOL/ ISIN: ARISTO/ INE082101010)

With reference to captioned subject and pursuant to Regulation 34 of SEBI (LODR) Regulation 2015 we hereby submit the stock exchange the 20th Annual Report (Revised) of the Company.

The following additional agendas are added in the Notice of 20th Annual General Meeting:

"6.TO APPROVE REVISION IN REMUNERATION PAYABLE TO MR. NARENDRA SINGH BARHAT (DIN: 00310306), CHAIRMAN AND MANAGING DIRECTOR OF THE COMPANY."

"7. TO APPROVE REVISION IN REMUNERATION PAYABLE TO MRS. KUSUM BARHAT (DIN: 00310065), EXECUTIVE DIRECTOR OF THE COMPANY"

AND

"8. TO APPROVE REVISION IN REMUNERATION PAYABLE TO MR. KETANKUMAR HARKANTBHAI JOSHI (DIN: 02089127), WHOLE TIME DIRECTOR OF THE COMPANY"

Kindly disseminate the same on your website and oblige us.

For, **Aristo Bio-tech and Lifescience Limited**
Narendra Singh Inder Singh Barhat
Digitally signed by Narendra Singh Inder Singh Barhat
Date: 2025.08.22 18:20:41 +05'30'
Narendra Singh Barhat
Chairman and Managing Director
DIN: 00310306

Place: Vadodara

Encl: 20th Annual Report (Revised) 2024-25

ARISTO BIO-TECH AND LIFESCIENCE LIMITED

PERIOD 2024-25

ANNUAL REPORT

INSIDE THIS REPORT

CONTENTS	PAGE NO.
CORPORATE INFORMATION	1-2
DIRECTORS' REPORT	3-16
• ANNEXURES TO DIRECTORS' REPORT	17-30
INDEPENDENT AUDITOR'S REPORT	31-40
BALANCE SHEET AS AT 31ST MARCH, 2025	41
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED ON 31ST MARCH, 2025	42
CASH FLOW STATEMENT FOR THE YEAR ENDED ON 31ST MARCH, 2025	43
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31ST MARCH, 2025	44-65
NOTICE OF 20TH ANNUAL GENERAL MEETING	66-79
• ANNEXURES TO NOTICE OF 20TH ANNUAL GENERAL MEETING	80-92

IMPORTANT COMMUNICATION TO SHAREHOLDERS

The Ministry of Corporate Affairs (MCA) has taken a "Green Initiative in the Corporate Governance" by allowing paperless compliance by the companies and has issued circulars stating that service of notice / documents including Annual Report can be sent through e-mail to the Shareholders. Further, in compliance with the provisions of the Companies Act, 2013, the Rules framed thereunder and the recent Circulars issued by the Ministry of Corporate Affairs (MCA) and the Securities and Exchange Board of India (SEBI), electronic copies of the Notice of the 20th Annual General Meeting (AGM) and the Annual Report for the Financial Year 2024-25 will be sent to all the Shareholders whose e-mail addresses are registered with the Company / Depository Participant(s). Shareholders may note that the Notice of the 20th AGM and the Annual Report 2024-25 will also be available on the Company's website (at www.aristobiotech.com), on the websites of the Stock Exchange where the Equity Shares of the Company are listed, i.e., National Stock Exchange of India Limited (at www.nseindia.com) and on the website of National Securities Depository Limited (NSDL) (at www.evoting.nsdl.com)

CORPORATE INFORMATION
ARISTO BIO-TECH AND LIFESCIENCE LIMITED
CIN: L01100GJ2005PLC127397

BOARD OF DIRECTORS:

NAME	DESIGNATION
Mr. Narendra Singh Barhat	Chairman & Managing Director
Mrs. Kusum Narendra Singh Barhat	Executive Director
Mr. Ketankumar Harkantbhai Joshi	Whole-Time Director
Mr. Laxman Singh Rathore	Non- Executive Director
Mr. Raghavender Mateti	Non- Executive Independent Director
Ms. Rashmi Kamlesh Otavani	Non- Executive Independent Director

KEY MANAGERIAL PERSONNEL:

NAME	DESIGNATION
Ms. Ayushi Aditya Deora*	Company Secretary and Compliance Officer
Mr. Ketankumar Harkantbhai Joshi	Chief Financial Officer
Ms. Diksha Jaipraksh Peswani **	Company Secretary and Compliance Officer

**Ms. Ayushi Aditya Deora has resigned w.e.f. May 29, 2025.*
***Ms. Diksha Peswani was appointed w.e.f. May 29, 2025.*

REGISTERED OFFICE	CORPORATE OFFICE
E-24, 25, 26, G.I.D.C., Ta. Savli, Manjusar, Vadodara-391775, Gujarat **TEL NO**. +91-2667-264841/264843 **EMAIL:**mail@aristobiotech.com/cs@aristobiotech.com ; **WEB:** www.aristobiotech.com	E-26, G.I.D.C., Ta. Savli, Manjusar, Vadodara-391775, Gujarat **TEL NO**. +91-2667-264841/264843 **EMAIL**:mail@aristobiotech.com/cs@aristobiotech.com **WEB**: www.aristobiotech.com

STATUTORY AUDITOR	SECRETARIAL AUDITOR
M/S. Prakash Chandra Jain & CO. Chartered Accountants (**FIRM REGISTRATION NO**. 002438C) **ADDRESS** – 74-76, Gayatri Chambers, Near Railway Station, Alkapuri, Vadodara – 390005, Gujarat.	**M/S SCS AND CO. LLP** Practicing Company Secretaries (**Firm Registration Number:** - L2020gj008700) **Address** – Office No. B- 1310, Thirteenth Floor, "Shilp Corporate Park" Rajpath Rangoli Road, Thaltej, Ahmedabad-380054

REGISTRAR & SHARE TRANSFER AGENT	BANKERS TO THE COMPANY:
MUFG Intime India Private Limited (Previously known as LINK Intime Private Limited) **CIN:** U67190MH1999PTC118368 **Address** – C -101, 247 Park, L B S Marg, Vikhroli West, Mumbai 400083; **Tel no**.022 - 4918 6000 **E-mail**: mumbai@in.mpms.mufg.com	Bank of Baroda

COMMITTEES OF BOARD:

AUDIT COMMITTEE		
NAME	CATEGORY	DESIGNATION
Mr. Laxman Singh Rathore*	Non-Executive Director	Chairperson
Mr. Raghavender Mateti	Non-Executive Independent Director	Member
Ms. Rashmi Kamlesh Otavani	Non-Executive Independent Director	Member

**After closure of year, at the Board Meeting held on July 04,2025 Mr. Laxman Singh Rathore was appointed as the Chairperson of the Audit Committee in place of Ms. Rashmi Otavani who was the Chairperson in previous years.*

STAKEHOLDER'S RELATIONSHIP COMMITTEE		
NAME	CATEGORY	DESIGNATION
Mr. Raghavender Mateti	Non-Executive Independent Director	Chairperson
Ms. Rashmi Kamlesh Otavani	Non-Executive Independent Director	Member
Mr. Laxman Singh Rathore	Non-Executive Director	Member

NOMINATION & REMUNERATION COMMITTEE		
NAME	CATEGORY	DESIGNATION
Mr. Raghavender Mateti	Non-Executive Independent Director	Chairperson
Ms. Rashmi Kamlesh Otavani	Non-Executive Independent Director	Member
Mr. Laxman Singh Rathore	Non-Executive Director	Member

DIRECTORS' REPORT

Dear Shareholders,

Your directors are pleased to present the report on the business and operations of your Company ("the Company") for the financial year ended March 31, 2025. This report is accompanied by the audited financial statements, which provide a comprehensive overview of the Company's financial performance and position during the year. We trust that the insights and information contained within these documents will offer a clear understanding of the Company's achievements and strategic direction.

FINANCIAL HIGHLIGHTS:

The Audited Financial Statements of your Company as on March 31, 2025, are prepared in accordance with the relevant applicable Accounting Standards ("AS") and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and the provisions of the Companies Act, 2013 ("Act").

(Rs. In Lakhs)

PARTICULARS	F.Y. 2024-25	F.Y. 2023-24
Revenue From Operations	31,809.27	24,514.79
Other Income	45.36	18.04
Total Income	**31,854.63**	**24,532.83**
Less: Total Expenses Before Depreciation, Finance Cost and Tax	30,881.92	23,665.59
Profit Before Depreciation, Finance Cost and Tax	972.71	867.24
Less: Depreciation	260.24	157.07
Less: Finance Cost	165.77	169.41
Profit Before Tax	**546.69**	**540.76**
Less: Short Provision of Taxes in Earlier Year	-	0.31
Less: Current Tax	144.07	138.69
Less: Deferred Tax Liability (Liability)	(3.69)	12.19
Profit After Tax	**406.31**	**389.57**
Earning Per Share (Basic & Diluted)	5.97	5.72

BUSINESS OVERVIEW

Financial Performance:

During the year under review, your Company has met and exceeded expectations, delivering a robust performance across all fronts. Revenue from operations witnessed a significant increase, rising from ₹24,514.79 lakhs in the financial year 2023–24 to ₹31,809.27 lakhs in 2024–25 — a growth of **29.75%**. This impressive performance was primarily driven by enhanced manufacturing output, improved production efficiency, and the successful adoption of advanced technologies.

The Company's growth momentum was supported by higher production volumes and operational efficiencies achieved at the manufacturing facility. As a result, the **Net Profit** for the financial year 2024–25 stood at ₹406.31 lakhs, as compared to ₹389.57 lakhs in the previous year, reflecting a **4.29% increase** year-on-year.

These financial results reinforce the effectiveness of the Company's strategic direction and business model, placing it in a strong position to pursue further growth and take on new challenges in the future.

Dividend:

Your Directors have recommended a dividend of Rs. 0.50 (Rupees fifty paisa only) per Equity Share of Rs. 10 each for FY 2024-25.

The dividend is subject to approval of shareholders at the ensuing Annual General Meeting ("AGM") and shall be subject to deduction of tax at source. The dividend, if approved by the shareholders, would involve a cash outflow of Rs. 34.04 Lakhs.

Unclaimed Dividends:

In terms of the Section 124 and 125 of the Act read with Investor Education and Protection Fund Authority (Accounting, Auditing, Transfer and Refund) Rules, 2016 (IEPF Rules), the dividend amount that remains unclaimed for a period of seven years or more is required to be transferred to the IEPF administered by the Central Government, along with the corresponding shares to the demat account of IEPF Authority.

As required in terms of the Secretarial Standard on Dividend (SS-3), details of unpaid dividend account and due dates of transfer to the IEPF is given below:

Sr No	Financial Year	Date of Declaration of Dividend	Due Date for Transfer to IEPF
1	2023-24	September 20, 2024	November 19, 2031
2	2022-23	September 26, 2023	November 25, 2030

The shareholders may note that both the unclaimed dividend and corresponding shares transferred to the IEPF Authority including all benefits accruing on such shares, if any, can be claimed back by them from IEPF Authority after following the procedure (i.e. an application in E-form No. IEPF-5) prescribed in the IEPF Rules. Shareholders may refer Rule 7 of the said IEPF Rules for refund of shares / dividend etc.

Transfer to General Reserve:

Your directors do not propose to transfer any amount to the Reserves for the financial year 2024-25. Instead, the total amount of net profit will be carried forward to the Reserves & Surplus, as reflected in the Balance Sheet of your Company.

Change in Nature of Business:

During the year, your Company has maintained its business operations and objectives without any changes. It continues to operate in the same line of business as outlined in the main object of the Company.

SHARE CAPITAL:

Authorized Capital:

During the year under review, there was no change in the Authorized share capital of your Company.

The Authorized Share Capital of your Company is Rs. 8,00,00,000/- (Rupees Eight Crores Only) divided into 8000000 (Eighty Lakhs Only) Equity Shares of Rs. 10/- (Rupees Ten Only) each.

Issued, Subscribed & Paid-up Capital:

During the year under review, there were no changes in the Issued, Subscribed, and Paid-up share capital of the Company.

The present Paid-up Capital of your Company is Rs. 6,80,78,000/-, divided into 68,07,800 Equity Shares of Rs. 10/- each.

Alteration of the Articles of Association of the company and Memorandum of Association:

During the year under review, there were no amendments or alterations made to the Memorandum of Association or the Articles of Association of the Company. The existing charter documents of the Company remain unchanged and continue to be in force.

BOARD OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:

Constitution of Board:

As on the date of this report, the Board comprises of the following Directors;

NAME OF DIRECTOR	CATEGORY CUM DESIGNATION	DATE OF ORIGINAL APPOINTMENT	DATE OF APPOINTMENT AT CURRENT TERM & DESIGNATION	*TOTAL DIRECTOR SHIPS IN ANOTHER CO.[1]	*NO. OF COMMITTEE[2]		NO. OF EQUITY SHARES HELD AS ON MARCH 31, 2025
					IN WHICH DIRECTOR IS MEMBERS	IN WHICH DIRECTOR IS CHAIRMAN	
Mr. Narendra Singh Barhat	Chairman and Managing Director	March 17, 2005	September 10, 2023	-	-	-	22,83,200
Mrs. Kusum Narendra Singh Barhat	Executive Director	March 17, 2005	March 17, 2005	-	-	-	6,25,000
Mr. Ketankumar Harkantbhai Joshi	Whole Time Director & CFO	August 27, 2018	March 20, 2022	-	-	-	7,20,000
Ms. Rashmi Kamlesh Otavani	Non-Executive Independent Director	March 20, 2022	April 06, 2022	4	5	1	-
Mr. Raghavender Mateti	Non-Executive Independent Director	September 10, 2018	September 09, 2023	-	2	1	-
Mr. Laxman Singh Rathore	Non-Executive Director	September 10, 2018	April 06, 2022	-	2	-	-

[1] Excluding Section 8 Company, Struck off Company, Amalgamated Company and LLPs.

[2] Committee Includes Audit Committee, Shareholders' Grievances & Relationship Committee Nomination & Remuneration Committee Across All Public Companies Including Our Company.
**As on March 31, 2025.*

The composition of Board complies with the requirements of the Companies Act, 2013 ("Act"). Further, in pursuance of Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), the Company is exempted from the requirement of having composition of Board as per Regulation 17 of Listing Regulations.

None of the Director of the Company is serving as a Whole-Time Director in any other Listed Company and the number of their directorship is within the limits laid down under section 165 of the Companies Act, 2013.

INFORMATION ON DIRECTORATE:

During the year under review, there were no changes took place in constitution of the Board of Directors of the Company.

A. Retirement by rotation and subsequent re-appointment:

Mr. Laxman Singh Rathore (DIN: 08218555), Non-Executive Director, is liable to retire by rotation at the ensuing Annual General Meeting, pursuant to Section 152 and other applicable provisions, if any, of the Companies Act, 2013, read with the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), and being eligible have offered himself for re-appointment.

Appropriate business for his re-appointment is being placed for the approval of the shareholders of the Company at the ensuing AGM. The brief resume of the Director and other related information has been detailed in the Notice convening the ensuing AGM of the Company.

The relevant details, as required under Regulation 36 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and Secretarial Standard, of the person seeking re-appointment/ appointment as Director are also provided in Notes to the Notice convening the 20th Annual General meeting.

Key Managerial Personnel:

During the financial year under review, there was no change in the Key Managerial Personnel of the Company. However, changes occurred after the closure of the financial year 2024–25 and up to the date of this report, as detailed below:

- **Cessation:**
  Subsequent to the closure of the financial year 2024–25, *Mrs. Ayushi Aditya Deodra* (Membership No. 70433) resigned from the position of Company Secretary and Compliance Officer of the Company with effect from May 29, 2025, due to personal reasons. She has confirmed that there were no other material reasons for her resignation.

- **Appointment:**
  Following the above resignation, *Ms. Diksha Jaiprakash Peswani* (Membership No: A76634) was appointed as the Company Secretary and Compliance Officer of the Company with effect from May 29, 2025.

As on the date of this report, the following individuals are designated as Key Managerial Personnel pursuant to Section 2(51) and Section 203 of the Companies Act, 2013:

- Mr. Narendra Singh Barhat - Chairman and Managing Director
- Mr. Ketankumar Harkantbhai Joshi – Whole Time Director & Chief Financial Officer (CFO)
- Ms. Diksha Jaiprakash Peswani - Company Secretary and Compliance Officer

Disclosure By Directors:

Your Directors have submitted notice of interest under Section 184(1) i.e. in Form MBP-1, intimation under Section 164(2) i.e. in Form DIR 8 and declaration as to compliance with the Code of Conduct of the Company.

Declaration From Independent Directors:

Your Company has received declarations from all the Independent Directors of your Company confirming that they meet the criteria of independence as prescribed under Section 149(6) of the Act and Regulation 16(1) (b) of the SEBI Listing Regulations and there has been no change in the circumstances which may affect their status as an Independent Director.

The Independent Directors have also given declaration of compliance with Rules 6(1) and 6(2) of the Companies (Appointment and Qualification of Directors) Rules, 2014, with respect to their name appearing in the data bank of Independent Directors maintained by the Indian Institute of Corporate Affairs.

Board Meeting:

The Board of Directors of the Company meets at regular intervals to deliberate on business opportunities, policies, strategies, and other key matters concerning the Company. In addition to scheduled meetings, the Board also convenes additional meetings as and when necessary.

During the year under review, Board of Directors of the Company met **8(Eight)** times i.e. on May 27, 2024, June 03, 2024, July 15, 2024, August 28, 2024, September 28, 2024, November 14, 2024, February 18, 2025 and March 10, 2025.

The Company has complied with the provisions of Section 173 of the Companies Act, 2013, and the time gap between any two consecutive Board Meetings did not exceed 120 days, as required under the Act.

The details of attendance of each Director at the Board Meetings and Annual General Meeting are given below:

NAME OF DIRECTOR	DESIGNATION	NUMBER OF BOARD MEETING HELD	NUMBER OF BOARD MEETINGS ELIGIBLE TO ATTEND	NUMBER OF BOARD MEETING ATTENDED	PRESENCE AT THE PREVIOUS AGM OF F.Y. 2024-25
Mr. Narendra Singh Barhat	Chairman and Managing Director	8	8	8	Yes
Mrs. Kusum Narendra Singh Barhat	Executive Director	8	8	8	Yes
Mr. Ketankumar Harkantbhai Joshi	Whole-Time Director	8	8	8	Yes
Mr. Laxman Singh Rathore	Non- Executive Director	8	8	8	Yes
Mr. Raghavender Mateti	Non- Executive Independent Director	8	8	8	Yes
Ms. Rashmi Kamlesh Otavani	Non- Executive Independent Director	8	8	8	Yes

GENERAL MEETINGS:

During the year under review, the following General Meeting was held, the details of which is given as under:

SR. NO.	TYPE OF GENERAL MEETING	DATE OF GENERAL MEETING
1	Annual General Meeting	September 20, 2024

Independent Directors:

In terms of Section 149 of the Companies Act, 2013 and rules made there under, the Company has 2 (Two) Non-Promoter Non-Executive Independent Directors in line with the act. The Company has received necessary declaration from each Independent Director under Section 149 (7) of the Companies Act, 2013 that they meet the criteria of independence laid down in Section 149 (6) of the Act.

Further, all the Independent Directors of the Company have registered themselves in the Independent Director Data Bank. In the opinion of the Board, all our Independent Directors possess requisite qualifications, experience, and expertise including the Proficiency and hold high standards of integrity for the purpose of Rule 8(5) of the Companies (Accounts) Rules, 2014.

A separate meeting of Independent Directors was held on March 10, 2025 to review the performance of Non-Independent Directors and Board as whole and performance of Chairperson of the Company including assessment of quality, quantity and timeliness of flow of information between Company management and Board.

Change In Registered Office:

During the year, there was no change in Registered Office of the Company. The Registered Office of the Company is situated at E-24, 25, 26, G.I.D.C. Manjusar, Ta. Savli, Vadodara-391 775.

Performance Evaluation:

Your Board of Directors have carried out an annual evaluation of its own performance, board committees and individual directors pursuant to the provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 in the following manners;

- The performance of the board was evaluated by the board, after seeking inputs from all the directors, on the basis of the criteria such as the board composition and structure, effectiveness of board processes, information and functioning etc.
- The performance of the committees was evaluated by the board after seeking inputs from the committee members on the basis of the criteria such as the composition of committees, effectiveness of committee meetings, etc.
- The board and the nomination and remuneration committee reviewed the performance of the individual directors on the basis of the criteria such as the contribution of the individual director to the board and committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution and inputs in meetings, etc.
- In addition, the chairman was also evaluated on the key aspects of his role.

Separate meeting of independent directors was held to evaluate the performance of non-independent directors, performance of the board as a whole and performance of the chairman, taking into account the views of executive directors and non-executive directors. Performance evaluation of independent directors was done by the entire board, excluding the independent director being evaluated.

DIRECTORS' RESPONSIBILITY STATEMENT:

Pursuant to section 134(5) of the Companies Act, 2013, the board of directors, to the best of their knowledge and ability, confirm that:

a) In preparation of annual accounts for the year ended March 31, 2025, the applicable accounting standards have been followed and that no material departures have been made from the same;

b) The Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for the year;

c) The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d) The Directors had prepared the annual accounts for the year ended March 31, 2025 on going concern basis.

e) The Directors had laid down the internal financial controls to be followed by the Company and that such Internal Financial Controls are adequate and were operating effectively; and

f) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

COMMITTEES OF BOARD

Your Board of Directors, in line with the requirement of the act, has formed various committees, details of which are given hereunder.

A. *Audit Committee:*

Your Company has formed audit committee in line with the provisions Section 177 of the Companies Act, 2013. Audit Committee meeting is generally held for the purpose of recommending the quarterly, half yearly and yearly financial result. Additional meeting is held for the purpose of reviewing the specific item included in terms of reference of the Committee.

During the year under review, Audit Committee met 4 (Four) times viz on May 27, 2024; August 28, 2024; November 14, 2024 and March 10, 2025.

The composition of the Committee and the details of meetings attended by its members are given below:

NAME	CATEGORY	DESIGNATION	NUMBER OF MEETINGS DURING THE FINANCIAL YEAR 2024-25	
			ELIGIBLE TO ATTEND	ATTENDED
Ms. Rashmi Kamlesh Otavani	Non-Executive Independent Director	Chairperson	4	4
Mr. Raghavender Mateti	Non-Executive Independent Director	Member	4	4
Mr. Laxman Singh Rathore	Non-Executive Director	Member	4	4

The Statutory Auditors of the Company are invited in the meeting of the Committee wherever requires as well as Company Secretary and Chief Financial Officer of the Company are regular invitees at the Meeting.

Recommendations of Audit Committee, wherever/whenever given, have been accepted by the Board of Directors.

Post Financial Year Update:

Following the closure of the financial year 2024–25, the Board of Directors, at their meeting held on July 04, 2025, reconstituted the Audit Committee; Mr. Laxman Singh Rathore was appointed as the Chairperson of the Committee in place of Ms. Rashmi, and Ms. Rashmi Kamlesh Otavani will continue to serve as a Member of the Committee.

Vigil Mechanism:

The Company has established a vigil mechanism and accordingly framed a Whistle Blower Policy. The policy enables the employees to report to the management instances of unethical behavior actual or suspected fraud or violation of Company's Code of Conduct.

Further the mechanism adopted by the Company encourages the Whistle Blower to report genuine concerns or grievances and provide for adequate safe guards against victimization of the Whistle Blower who avails of such mechanism and also provides for direct access to the Chairman of the Audit Committee in exceptional cases.

The functioning of vigil mechanism is reviewed by the Audit Committee from time to time. None of the Whistle blowers has been denied access to the Audit Committee of the Board. The Whistle Blower Policy of the Company is available on the website of the Company https://www.aristobiotech.com/investors/policies.

B. *Stakeholder's Grievance & Relationship Committee:*

Your Board of Directors have constituted Stakeholder's Grievance & Relationship Committee mainly to focus on the redressal of Shareholders' / Investors' Grievances, if any, like Transfer / Transmission / Demat of Shares; Loss of Share

Certificates; Non-receipt of Annual Report; Dividend Warrants; etc. The Stakeholders Relationship Committee shall report to the Board on a quarterly basis regarding the status of redressal of complaints received from the shareholders of the Company.

During the year under review, Stakeholder's Grievance & Relationship Committee met 4 (Four) time i.e. on May 27, 2024; August 28, 2024; November 14, 2024 and March 10, 2025.

The composition of the Committee and the details of meetings attended by its members are given below:

NAME	CATEGORY	DESIGNATION	NUMBER OF MEETINGS DURING THE FINANCIAL YEAR 2024-25	
			ELIGIBLE TO ATTEND	ATTENDED
Ms. Rashmi Kamlesh Otavani	Non-Executive Independent Director	Member	4	4
Mr. Raghavender Mateti	Non-Executive Independent Director	Chairperson	4	4
Mr. Laxman Singh Rathore	Non-Executive Director	Member	4	4

The Company Secretary of the company present in all meetings of Stakeholder's Grievance & Relationship Committee held during the year.

Also, during the year, the Company had not received any complaints from the Shareholders. There was no complaint pending as on March 31, 2025.

C. *Nomination and Remuneration Committee:*

Your Board of Directors have formed Nomination and Remuneration committee in line with the provisions of Section 178 of the Companies Act, 2013.

Nomination and Remuneration Committee meetings are generally held for identifying the persons who are qualified to become Directors and may be appointed in senior management and recommending their appointments and removal.

During the year under review, Nomination and Remuneration Committee met 2 (Two) times, viz on August 28, 2024 and March 10, 2025.

The composition of the Committee and the details of meetings attended by its members are given below:

NAME	CATEGORY	DESIGNATION	NUMBER OF MEETINGS DURING THE FINANCIAL YEAR 2024-25	
			ELIGIBLE TO ATTEND	ATTENDED
Mr. Raghavender Mateti	Non-Executive Independent Director	Chairperson	2	2
Ms. Rashmi Kamlesh Otavani	Non-Executive Independent Director	Member	2	2
Mr. Laxman Singh Rathore	Non-Executive Director	Member	2	2

Nomination and Remuneration Policy:

Nomination and Remuneration Policy in the Company is designed to create a high-performance culture. It enables the Company to attract motivated and retained manpower in competitive market, and to harmonize the aspirations of

human resources consistent with the goals of the Company. The Company pays remuneration by way of salary, benefits, perquisites and allowances to its Executive Directors and Key Managerial Personnel. Annual increments are decided by the Nomination and Remuneration Committee within the salary scale approved by the members and are effective from April 1, of each year.

The Nomination and Remuneration Policy, as adopted by the Board of Directors, is placed on the website of the Company at https://www.aristobiotech.com/investors/policies

Remuneration of Director:

The details of remuneration paid during the financial year 2024-25 to directors of the Company is provided in Form MGT-7 available at website of the Company, i.e. https://www.aristobiotech.com/investors.

Public Deposit:

Your company has not accepted any deposits from the public. Hence, the directives issued by the Reserve Bank of India & the Provision of Section 73 to 76 of the Company Act, 2013 or any other relevant provisions of the Act and the Rules there under are not applicable.

Particulars Of Loans, Guarantees, Investments & Security:

Details of Loans, Guarantees, Investments and Security covered under the provisions of Section 186 of the Companies Act, 2013 are given in the notes to the Financial Statement.

Annual Return:

Pursuant to Section 134(3)(a) of the Act, the draft annual return as on March 31, 2025 prepared in accordance with Section 92(3) of the Act is made available on the website of your Company and can be accessed using the https://www.aristobiotech.com/investors.

Subsidiaries Associates and Joint Venture of the Company:

As on March 31, 2025 Your Company does not have any Subsidiary, Associate and Joint Venture Company.

Transactions with Related Parties:

All Related Party Transactions entered into by the Company during the financial year under review were in the Ordinary Course of Business and on an Arm's Length basis, in compliance with the applicable provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable to SME listed entities.

There were no materially significant Related Party Transactions:

- Exceeding 10% of the annual consolidated turnover of the Company, or
- Involving brand usage or royalty payments exceeding 5% of the annual consolidated turnover,

that may have a potential conflict with the interest of the Company at large.

Accordingly, the disclosure of particulars of contracts or arrangements with related parties in Form AOC-2, as required under Section 134(3)(h) of the Companies Act, 2013, is not applicable.

The Company has a mechanism in place to obtain prior omnibus approval of the Audit Committee for transactions which are repetitive and of a foreseen nature. All such related party transactions entered into under omnibus approval are reviewed and placed before the Audit Committee and the Board on a quarterly basis.

The details of the related party transactions for the Financial Year 2024–25 are provided in the notes to the financial statements, which form an integral part of this Annual Report.

The Company's Policy on Related Party Transactions, as approved by the Board of Directors, is available on the Company's website and can be accessed at: https://www.aristobiotech.com/investors/policies.

Material Changes and Commitment:

There were no material changes or commitments that have occurred during the financial Year or between the end of the financial year on March 31, 2025 and the date of this Report that would affect the financial position of the Company.

Particular of Employees:

The ratio of the remuneration of each director to the median of employees' remuneration as per Section 197(12) of the Companies Act, 2013, read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is annexed to this Report as "**Annexure-A**".

Sexual Harassment of Women at Workplace:

The Company has always fostered a safe and inclusive work environment for all employees. In compliance with the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, the Company has constituted an Internal Complaints Committee (ICC) at all its workplace locations.

The Company has adopted a Prevention of Sexual Harassment Policy that ensures protection against sexual harassment and provides a framework for addressing complaints in a gender-neutral and confidential manner.

During the year under review,

a. Number of complaints filed during the financial year - **NIL**

b. Number of complaints disposed of during the financial year – **NIL**

c. Number of complaints pending as on end of the financial year – **NIL**

The Policy is available on the Company's website at: https://www.aristobiotech.com/investors/policies.

Compliance to the provisions relating to the Maternity Benefits Act, 1961

The company is in Compliance with the Maternity Benefit Act, 1961. However, no maternity benefit was claimed during the year.

Details Of Difference Between Amount of The Valuation Done at The Time of One Time Settlement and the Valuation Done While Taking Loan from the Banks or Financial Institutions Along with The Reasons Thereof

No such instances occurred during the financial year.

Risk Management:

A well-defined risk management mechanism covering the risk mapping and trend analysis, risk exposure, potential impact \and risk mitigation process is in place. The objective of the mechanism is to minimize the impact of risks identified and taking advance actions to mitigate it. The mechanism works on the principles of probability of occurrence and impact, if triggered. A detailed exercise is being carried out to identify, evaluate, monitor and manage both business and non-business risks.

Energy Conservation, Technology Absorption and Foreign Exchange Earnings and Outgo:

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo stipulated under Section 134(3) (m) of the Act read with rule 8 of The Companies (Accounts) Rules, 2014, as amended from time to time is annexed to this Report as "**Annexure - B**".

Compliance With the Provisions of Secretarial Standard 1 And Secretarial Standard 2:

The Company has devised proper systems to ensure compliance with the provisions of all applicable Secretarial Standards issued by the Institute of Company Secretaries of India and that such systems are adequate and operating effectively. During the year under review, the Company has complied with the applicable Secretarial Standards issued by the Institute of Company Secretaries of India, New Delhi.

Internal Financial Control Systems and Their Adequacy:

The Company has an effective internal control system, which ensures that all the assets of the Company are safeguarded and protected against any loss from unauthorized use or disposition.

The Internal Auditors of the Company carry out review of the internal control systems and procedures. The internal audit reports are reviewed by Audit Committee.

The Company has also put in place adequate internal financial controls with reference to the financial statements commensurate with the size and nature of operations of the Company. During the year, such controls were tested and no material discrepancy or weakness in the Company's internal controls over financial reporting was observed.

Corporate Governance:

Integrity and transparency are key factors to our corporate governance practices to ensure that we achieve and will retain the trust of our stakeholders at all times. Corporate governance is about maximizing shareholder value legally, ethically and sustainably. Our Board exercises its fiduciary responsibilities in the widest sense of the term. Our disclosures seek to attain the best practices in international corporate governance. We also endeavor to enhance long-term shareholder value and respect minority rights in all our business decisions.

As our company has been listed on EMERGE Platform of National Stock Exchange of India Limited, by virtue of Regulation 15 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 the compliance with the corporate Governance provisions as specified in regulation 17 to 27 and Clause (b) to (i) of sub regulation (2) of Regulation 46 and Para C D and E of Schedule V are not applicable to the company. Hence Corporate Governance Report does not form a part of this Board Report, though we are committed for the best corporate governance practices.

Corporate Social Responsibility (CSR):

During the year under review, Provisions pertaining to Corporate Social Responsibility of Section 135 of the Companies Act, 2013 are not applicable to the Company.

Management Discussion and Analysis Report:

In terms of Regulation 34, and Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 a review of the performance of the Company, for the year under review, Management Discussion and Analysis Report, is presented in a separate section forming part of this Annual Report as "**Annexure C**".

Statutory Auditor and their Report:

Pursuant to the provisions of Section 139 of the Act read with rules made thereunder, as amended from time to time, M/s. Prakash Chandra Jain & Co., Chartered Accountants (FRN: 002438C), were appointed as Statutory Auditors to hold office until the conclusion of this Annual General Meeting (AGM).

M/s. Prakash Chandra Jain & Co., Chartered Accountants (FRN: 002438C), proposed to be re-appointed as Statutory Auditors of your Company at forthcoming Annual General Meeting, for the second term of four consecutive years for a term till the conclusion of Annual General Meeting to be held in the calendar year 2029.

Considering their performance and based on the Board's recommendation, the firm has been reappointed for a further period of four financial years, commencing from FY 2025–26 and continuing until the conclusion of the AGM to be held in FY 2028–29.

The Notes to the financial statements referred in the Auditors Report are self-explanatory and therefore do not call for any comments under Section 134 of the Companies Act, 2013. The Auditors' Report is enclosed with the financial statements in this Annual Report. There has been no qualification, reservation, adverse remark or disclaimer given by the Auditors in their Report.

Internal Auditor:

In accordance with the provisions of Section 138 of the Companies Act, 2013, the Board of Directors had appointed M/s D.C. Parikh & Co., Chartered Accountants (Firm Reg. No. 107537W), Vadodara, as the Internal Auditor of the Company for the financial year 2024–25.

They have conducted periodic internal audits of various operational and financial functions and submitted their reports to the Audit Committee and the Board. Their observations and recommendations have helped strengthen the internal control systems and ensure compliance.

Maintenance of Cost Record:

Pursuant to the provisions of the Companies Act, 2013 and rules thereof, the Board of Directors of your Company, have appointed M/s. YS THAKAR & CO, Cost Accountants (Firm Registration No.: 000318), as the Cost Auditor of the Company to audit the cost records of the Company for the financial year 2024-25.

Pursuant to the provisions of the Companies Act, 2013 and rules thereof, the Board of Directors of your Company, in their meeting held on August 28, 2024, on the recommendation of the Audit Committee, have appointed M/s. YS THAKAR & CO, Cost Accountants (Firm Registration No.: 000318) as the Cost Auditor of the Company to audit the cost records of the Company for the financial year 2024-25. M/s. YS THAKAR & CO, have confirmed that they are free from disqualification specified under Section 141(3) and proviso to Section 148(3) read with Section 141(4) of the Act and that their appointment meets the requirements of Section 141(3) (g) of the Act. They have further confirmed their independent status and an arm's length relationship with the Company. Further, as per Section 148 of the Companies Act, 2013, the remuneration payable to the Cost Auditor is required to be ratified at the ensuing Annual General Meeting.

Your Company has maintained cost accounts and records in accordance with provisions of Section 148 of the Companies Act, 2013 and rules thereof.

Secretarial Auditor and their Report:

In compliance with the provisions of Section 204 of the Companies Act, 2013, read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company has appointed M/s. SCS & Co. LLP, Practicing Company Secretaries, Ahmedabad, as the Secretarial Auditor to carry out the Secretarial Audit for the financial year 2024–25.

The Secretarial Audit Report is annexed as "**Annexure – D**" to this Board Report.

There have been few common annotations reported by the above Secretarial Auditors in their Report with respect to:

SR. NO.	COMPLIANCE REQUIREMENT (REGULATIONS/ CIRCULARS / GUIDELINES INCLUDING SPECIFIC CLAUSE)	DEVIATIONS	OBSERVATIONS/ REMARKS OF THE PRACTICING COMPANY SECRETARY
1	Regulation 3(5) & 3(6) SEBI (Prohibition of Insider Trading) Regulations, 2015.	It was reported that the Company had delays in entering certain Unpublished Price Sensitive Information (UPSI) entries into the Structured Digital Database (SDD) software. Further, the flow of information related to some of these entries was found to be incorrect.	The Company has strengthened its internal processes for timely and accurate recording of UPSI in the SDD. Additionally, a clear accountability framework has been established to prevent recurrence of such lapses.

Further, Few ROC forms have been filed delayed with additional fees by the company for the financial year 2024-25.

Reply by Management: The Company has taken note of the observations of the Practicing Company Secretary regarding delays in entering certain Unpublished Price Sensitive Information (UPSI) into the Structured Digital Database (SDD) and instances of incorrect flow of information for some entries. The management has since strengthened the internal control framework to ensure timely and accurate recording of UPSI in the SDD, along with establishing a clear accountability mechanism to avoid recurrence of such lapses.

With respect to the delays in filing certain ROC forms for the financial year 2024-25, the management clarifies that these were procedural in nature and have since been duly filed with payment of applicable additional fees. The Company is committed to adhering to all statutory timelines and has implemented improved monitoring systems to ensure timely compliance going forward.

Reporting of Fraud:

During the year under review, the Statutory Auditors and Secretarial Auditor of your Company have not reported any instances of fraud committed in your Company by Company's officers or employees, to the Audit Committee, as required under Section 143(12) of the Act.

Significant/Material Orders passed by the Regulators:

There are no other significant/material orders passed by the Regulators, Courts, Tribunals, Statutory and quasi-judicial body impacting the going concern status of the Company and its operations in future.

The details of litigation on tax and other relevant matters are disclosed in the Auditors' Report and Financial Statements which forms part of this Annual Report.

Corporate Insolvency Resolution Process Initiated Under the Insolvency and Bankruptcy Code, 2016 (IBC):

During the period under review no corporate insolvency resolution process is initiated against the company under the Insolvency and Bankruptcy Code, 2016 (IBC).

Website:

Your Company has its fully functional website www.aristobiotech.com which has been designed to exhibit all the relevant details about the Company. The site carries a comprehensive database of information of the Company including the Financial Results of your Company, Shareholding Pattern, details of Board Committees, Corporate Policies/ Codes, business activities and current affairs of your Company.

All the mandatory information and disclosures as per the requirements of the Companies Act, 2013, Companies Rules, 2014 and as per Regulation 46 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and also the non-mandatory information of Investors' interest / knowledge has been duly presented on the website of the Company.

Code For Prevention of Insider Trading:

Your Company has adopted a Code of Conduct ("Code") to regulate, monitor and report trading in Company's shares by Company's designated persons and their immediate relatives as per the requirements under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The Code, inter alia, lays down the procedures to be followed by designated persons while trading/ dealing in Company's shares and sharing Unpublished Price Sensitive Information ("UPSI"). The Code Covers Company's obligation to maintain a digital database, mechanism for prevention of insider trading and handling of UPSI, and the process to familiarize with the sensitivity of UPSI. Further, it also includes code for practices and procedures for fair disclosure of unpublished price sensitive information which has been made available on the Company's website at https://www.aristobiotech.com/investors

The employees are required to undergo a mandatory training/ certification on this Code to sensitize themselves and strengthen their awareness.

General Disclosure:

Your Directors state that the Company has made disclosures in this report for the items prescribed in section 134 (3) of the Act and Rule 8 of The Companies (Accounts) Rules, 2014 and other applicable provisions of the act and listing regulations, to the extent the transactions took place on those items during the year.

Your directors further state that no disclosure or reporting is required in respect of the following items as there were no transactions on these items during the year under review;

(i) Issue of Equity Shares with differential rights as to dividend, voting or otherwise;

(ii) Issue of shares (including sweat equity shares) to employees of the Company under any scheme save and ESOS;

(iii) Annual Report and other compliances on Corporate Social Responsibility;

(iv) There is no revision in the Board Report or Financial Statement;

(v) No significant or material orders were passed by the Regulators or Courts or Tribunals which impact the going concern status and Company's operations in future;

(vi) Information on subsidiary, associate and joint venture companies.

(vii) The details of difference between amount of the valuation done at the time of one-time settlement and the valuation done while taking loan from the Banks or Financial Institutions along with the reasons thereof

Appreciations and Acknowledgement:

Your directors wish to place on record their sincere appreciation for significant contributions made by the employees at all levels through their dedication, hard work and commitment during the year under review.

Your Board places on record its appreciation for the support and co-operation your Company has been receiving from its suppliers, distributors, retailers, business partners and others associated with it as its trading partners. Your Company looks upon them as partners in its progress and has shared with them the rewards of growth. It will be your Company's endeavor to build and nurture strong links with the trade based on mutuality of benefits, respect for and co-operation with each other, consistent with consumer interests.

Your directors also take this opportunity to thank all Shareholders, Clients, Vendors, Banks, Government and Regulatory Authorities and Stock Exchanges, for their continued support.

For and on behalf of Board of Directors
Aristo Bio-Tech and Lifescience Limited
CIN: L01100GJ2005PLC127397

Registered office:
E-24/25/26, G.I.D.C., Ta. Savli,
Manjusar, Vadodara-391775,Gujarat

Narendra Singh Barhat
Chairman and Managing Director
DIN: 00310306

Ketankumar Harkantbhai Joshi
Whole Time Director & CFO
DIN: 02089127

Place: Vadodara
Date: August 14, 2025

ANNEXURE-A

PARTICULARS OF EMPLOYEES
(Pursuant to Section 197(12) read with Rules made thereunder)
Disclosures pertaining to remuneration and other details as required under Section 197(12) of the Companies Act, 2013 read with Rules made there under.

Information pursuant to Section 197 of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

A. The ratio of remuneration of each director to the median remuneration of employees for the financial year and the percentage increase in remuneration of each director, chief financial officer, chief executive officer, company secretary or manager, if any, in the financial year:

SR. NO.	NAME OF DIRECTOR	DESIGNATION	NATURE OF PAYMENT	RATIO OF REMUNERATION TO MEDIAN REMUNERATION OF EMPLOYEES	% INCREASE/ DECREASE IN REMUNERATION IN THE FINANCIAL YEAR
1	Mr. Narendra Singh Barhat	Chairman and Managing Director	Remuneration	19.43:1	No change
2	Mr. Ketankumar Harkantbhai Joshi	Whole-Time Director and CFO	Remuneration	10.93:1	No change
3	Mrs. Kusum Narendra Singh Barhat	Executive Director	Remuneration	10.93:1	No change
4	*Mrs. Ayushi Aditya Deodra	Company Secretary	Remuneration	0.87:1	NA

** Mrs. Ayushi Deora was appointed as Company Secretary & Compliance Officer w.e.f March 19, 2024 and has resigned w.e.f. May 29, 2025.*

B. The percentage increase / decrease in the median remuneration of employees in the financial year:

The median remuneration of the employees in current financial year has increased by 4% over the previous financial year.

C. The number of permanent employees on the rolls of company:

Total 66 Permanent Employees were on roll in the company as on March 31, 2025.

D. Average percentile increases already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration:

The Average salary of employee has decreased by 2.94% of employees in comparison to previous year, whereas the remuneration of the executive directors remains unchanged and it was within the limit as approved by the shareholders of the Company.

E. Affirmation that the remuneration is as per the remuneration policy of the company:

The Company affirms remuneration is as per the Remuneration Policy of the Company.

For and on behalf of Board of Directors
Aristo Bio-Tech and Lifescience Limited
CIN: L01100GJ2005PLC127397

Registered office:
E-24/25/26, G.I.D.C., Ta. Savli,
Manjusar, Vadodara-391775,Gujarat

Place: Vadodara
Date: August 14, 2025

Narendra Singh Barhat
Chairman and Managing Director
DIN: 00310306

Ketankumar Harkantbhai Joshi
Whole Time Director & CFO
DIN: 02089127

ANNEXURE-B

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO
[Pursuant to Section 134(3) (m) of the Companies Act, 2013 and rule 8(3) of the Companies (Accounts) Rules, 2014]

A. CONSERVATION OF ENERGY:

i. Steps taken or impact on conservation of energy:

Initiatives to integrate energy efficiency into overall operations are undertaken through design considerations and operational practices. The key initiatives towards conservation of energy are:

- Improved monitoring of energy consumption through smart metering and integration with building management systems;
- Continuously replacing the inefficient equipment with latest energy efficient technology and up gradation of equipment's continually;
- Increasing the awareness of energy saving within the organization to avoid wastage of energy.

ii. Steps taken by the Company to utilize alternate source of energy:

NIL

iii. Capital investment on energy conservation equipment:

During the year under review, Company has not incurred any capital investment on energy conservation equipment.

B. TECHNOLOGY ABSORPTION:

i. The efforts made towards technology absorption:

No special efforts made towards technology absorption. However, your Company continues its commitment to up the quality by absorbing the latest technology.

ii. Benefits derived like product improvement, cost reduction, product development or import substitution:

- Cost optimization
- Improvement in quality of products

iii. In case of imported technology (imported during the last three years reckoned from the beginning of financial year) :

a) The details of technology imported: None
b) The year of import: None
c) Whether the technology has been fully absorbed: None
d) If not fully absorbed, areas where absorption has not taken place, and the reasons thereof: None

iv. Expenditure incurred on Research & Development – Not Applicable

C. FOREIGN EXCHANGE EARNINGS AND OUTGO:

(Rs. in Lakhs)

PARTICULARS	F.Y. 2024-25	F.Y. 2023-24
Export Sales	489.53	793.07
Import Purchases	2130.49	630.24

For and on behalf of Board of Directors
Aristo Bio-Tech and Lifescience Limited
CIN: L01100GJ2005PLC127397

Registered office:
E-24/25/26, G.I.D.C., Ta. Savli,
Manjusar, Vadodara-391775,Gujarat

Place: Vadodara
Date: August 14, 2025

Narendra Singh Barhat
Chairman and Managing Director
DIN: 00310306

Ketankumar Harkantbhai Joshi
Whole Time Director & CFO
DIN: 02089127

ANNEXURE-C

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

The discussion hereunder covers Company's performance and its business outlook for the future. This outlook is based on assessment of the current business environment and Government policies. The change in future economic and other developments are likely to cause variation in this outlook.

The Management's views on the Company's Performance and outlook are discussed below:

GLOBAL ECONOMY:

The global macroeconomic landscape faces significant headwinds in the year ahead, characterized by decelerating growth, persistent geopolitical tensions, and a cautious recalibration of monetary policy. A key driver of this slowdown is the intensification of trade disputes—most notably, the implementation of U.S. tariffs, including a 10% baseline levy and elevated duties on Chinese imports. These measures have disrupted global trade flows, provoked retaliatory actions, and heightened policy uncertainty, collectively dampening investor confidence, curbing capital expenditures, and sustaining inflationary pressures.

The International Monetary Fund (IMF) projects global GDP growth at 2.8% for 2025, slightly outpacing the World Bank's estimate of 2.3%. While global inflation is expected to decline to 4.2%, the disinflationary trajectory will likely be uneven, with advanced economies on track to meet central bank targets ahead of their emerging market counterparts.

Trade performance is expected to weaken significantly, with global trade volumes forecast to grow by just 1.7% in 2025—a notable drop from 3.8% in the prior year. This decline reflects the compounded effects of escalating trade restrictions and mounting policy ambiguity. As a result, stakeholders across the public and private sectors are closely monitoring developments in energy markets, global supply chains, and key international trade corridors.

INDIAN ECONOMY:

India's GDP growth is projected at 6.5% for FY25, underpinned by strong domestic consumption, increased government expenditure, and a more accommodative monetary policy stance. To bolster investment and economic activity, the Reserve Bank of India (RBI) has implemented a 100-basis point reduction in the repo rate, with additional easing anticipated in the latter half of 2025.

Both the International Monetary Fund (IMF) and Moody's forecast a 6.5% growth rate for FY26, citing resilient domestic demand and continued fiscal support as key drivers. India's economy does not require revival—it requires strategic resilience management and structural acceleration. Should current policy momentum be maintained and global geopolitical tensions subside, India is well-positioned to exceed 7% growth in FY26, supported by contained inflation and strengthened investor confidence.

INDUSTRY STRUCTURE AND DEVELOPMENTS- INDIAN AGROCHEMICAL SECTOR:

The global agrochemical industry has witnessed significant growth over the past decade and is projected to reach a valuation of over USD 390 billion by 2025. This growth is primarily driven by the increasing global population, rising demand for food security, and the continued need for higher agricultural productivity. Asia-Pacific remains the largest market, with India and China leading consumption. Technological advancements, such as the use of artificial intelligence (AI) in pesticide development and RNA-based pesticide innovations, are transforming how agrochemicals are discovered and applied, enhancing both efficiency and environmental safety.

However, the industry faces ongoing challenges, including pesticide resistance especially among weeds and rising scrutiny over the environmental and health impacts of chemical usage.

Recognizing the pivotal role of the agrochemical industry, the Indian government has identified it as one of the top 12 sectors to attain global leadership, with a projected growth rate of 8-10% through 2025, as reported by the Federation of Indian Chambers of Commerce and Industry (FICCI).

Approximately 30–35% of India's annual crop yield is lost due to pests, weeds, and diseases, as reported by the Indian Council of Agricultural Research (ICAR). Agrochemicals, including pesticides and fungicides, play a crucial role in mitigating these losses by protecting crops from various threats.

However, the industry faces challenges such as stiff competition from cheap imports, particularly from China, which can impact profit margins for Indian producers. Moreover, global economic slowdowns and unpredictable weather patterns pose additional challenges by causing fluctuations in demand for agrochemicals. Despite these challenges, the Indian agrochemicals sector remains resilient, driven by innovation, strategic investments, and a favorable regulatory environment.

INDUSTRY DRIVERS:

The key factors of driving the agrochemical industry are:

- **Rising Global Population and Food Demand:** The world population is projected to exceed 9.7 billion by 2050, significantly increasing food consumption. This surge in demand pressures the agricultural sector to boost productivity, particularly in regions already facing food insecurity. Agrochemicals, such as fertilizers, herbicides, fungicides, and insecticides, are crucial in achieving high crop yields and preventing crop loss due to pests and diseases.

- **Declining Arable Land per Capital:** Rapid urbanization, industrial expansion, and soil degradation are shrinking the amount of arable land. Farmers are forced to intensify production on limited land, which requires efficient use of agrochemicals. The need to maintain or increase yield per unit of land is a primary growth factor for the agrochemical industry.

- **Government initiatives to promote agriculture:** Many governments subsidize fertilizers and pesticides to support agricultural productivity. These regulations drive innovation in eco-friendly, low-toxicity formulations. Additionally, initiatives are being undertaken to improve soil health, strengthen credit facilities, crop insurance and infrastructure. A notable initiative, the "Digital Agriculture Mission," has been launched to modernize the agricultural sector and leverage the benefits of digital technologies. These collective endeavors are aimed at driving growth and ensuring the sustainability of agriculture sector.

- **Increasing Consumer Demand for Quality and Safety:** Rising consumer awareness of food safety and environmental sustainability affects market dynamics. Organic and residue-free farming practices are gaining traction, boosting the demand for biological agrochemicals. Agrochemical companies are developing solutions that meet both productivity goals and sustainability standards.

- **Private Sector Investment and Strategic Partnerships:** The agrochemical industry is seeing increased investments, M&A activity, and partnerships with aggrotech startups. Strategic alliances with biotechnology firms and AI-driven aggrotech platforms enhance product pipelines and market reach. Private equity and venture capital are investing in sustainable and precision farming innovations, accelerating industry evolution.

- **Climate Change and Environmental Stress:** Unpredictable weather patterns, droughts, floods, and extreme temperatures are becoming more frequent due to climate change. These conditions create favorable environments for pests and plant diseases, increasing the need for crop protection chemicals. Agrochemicals are used to mitigate biotic and abiotic stress, ensuring consistent crop performance under adverse conditions.

- **Increasing investment in agricultural research and development (R&D):** The Indian agriculture industry is currently witnessing a steady rise in research and development endeavors. Substantial investments in R&D initiatives are driving the deployment of enhanced technologies, improved supply chain systems, and the utilization of organic materials for the production of top-notch agricultural goods. These remarkable advancements are bolstering productivity, elevating product quality, and fostering overall growth within the industry.

COMPANY OVERVIEW AND OUTLOOK:



Our Company was originally incorporated on March 17, 2005 as "Aristo Bio-Tech and Lifescience Private Limited" under the provisions of the Companies Act, 1956 with the Registrar of Companies, Maharashtra, Mumbai. Subsequently our Company was converted into Public Limited Company and name of company was changed from "Aristo Bio-Tech and Lifescience Private Limited" to "Aristo Bio-Tech and Lifescience Limited" vide fresh certificate of incorporation dated May 20, 2020 issued by the Registrar of Companies, Mumbai. Further our Company has changed the registered office from State of Maharashtra to Gujarat vide Certificate of Registration of Regional Director order for Change of State dated November 18, 2021 issued by Registrar of Companies, Ahmedabad.

Our Company is an agrochemical company engaged in the manufacturing, formulation, supplying, packaging and job work services in various Pesticides such as Insecticides, Herbicides, Fungicides, Plant Growth Regulators and a wide variety of other Agrochemicals for India as well as for Export. Agrochemical industries are very vast field and deals with production and distribution of pesticides and fertilizers to increase the crop yields. Agrochemicals (Crop protection products/pesticides) are designed to protect crops from insects, diseases and weeds. Currently our company has 257 products registered with CIB&RC for manufacturing and sales.

Our Company supplies its products across 20 states i.e. Assam, Andhra Pradesh, Bihar, Chhattisgarh, Gujarat, Haryana, Jammu & Kashmir, Jharkhand, Karnataka, Kerala, Madhya Pradesh, Maharashtra, Odisha, Punjab, Rajasthan, Tamil Nadu, Telangana, Uttarakhand, Uttar Pradesh, West Bengal and 15 Countries i.e. Armenia, Australia, Bangladesh, Belgium, Cambodia, Germany, Italy, Kenya, Moldova, New Zealand, Poland, South Africa, UAE, Ukraine and Vietnam.

Our Company is manufacturing agrochemicals such as Insecticides, Herbicides, Fungicides and Plant Growth Regulators which are directly sold to our customers and is also engaged in job work as per customer requirements.

Our company has adequate production and quality control system. All formulations are strictly tested with the latest available guidelines and testing methods by our in-house Quality Control Lab personnel. High Performance Liquid Chromatography (HPLC), Ultraviolet Spectrograph (UV) and Gas Chromatography (GC) are used to ensure top quality Raw materials and formulation testing and release. Strict testing for all Packing materials like Tin, HDPE bottles, Coextruded bottles, Fluorinated HDPE bottles, Pet bottles, Labels, Mono cartons, Corrugated boxes, Laminated pouches is also done as per the Food and Agriculture Organization of the United Nations (FAO) and Bureau of Indian Standards (BIS) guidelines and testing methods. All Finished goods are re-tested and counter samples are stored separately in sample storage rooms.

OPPORTUNITIES AND THREATS:

Opportunities:

- Feeding the growing India and global population. With rising population, the government is focused on the food security of the nation. With India's population set to exceed 1.5 billion by 2030, there is an urgent focus on developing sustainable solutions for long-term food production.

- Protecting crops from pests, diseases, and environmental stressors remains critical to ensuring food security and supporting economic growth. By adopting more advanced crop protection measures and innovative farming practices, governments can mitigate losses and maintain a stable food supply.

- Precision farming technologies are expected to redefine modern agriculture by 2025. With advancements in AI, IoT, drones, and data analytics, precision farming is becoming more accessible and scalable.

- Agrochemicals are increasingly seen as vital tools for mitigating the impacts of climate change on agriculture. With unpredictable weather patterns, pests, and disease outbreaks becoming more frequent, agrochemicals are crucial in maintaining crop health and resilience.

Threats:

- The agrochemical industry is grappling with growing regulatory scrutiny, particularly regarding the approval process for new molecules. The slow pace of regulatory approvals for new agrochemical products is a significant barrier to innovation.

- With tighter environmental and safety regulations, any lapses or non-compliance can lead to severe penalties, product recalls, or even license suspensions.

- The erratic nature of rainfall, a result of climate change, is disrupting traditional agricultural cycles. This volatility affects the timing of sowing and harvesting, and in turn, impacts the demand for agrochemicals.

- The growing resistance of pests to conventional pesticides is a major challenge that the agrochemical industry is facing. This resistance reduces the effectiveness of existing pest control solutions, posing a serious threat to crop protection efforts

- Agrochemical inventories have been at elevated levels after the kharif season, because of the erratic rainfalls and weak demand. This has led to higher sales returns and a decline in profitability for agrochemical companies.

- The pace of change in both the agrochemical market and adjacent industries is accelerating. Companies must stay agile to meet evolving customer needs, regulatory requirements, and market dynamics.



Risk and Concerns:

A well-defined risk management mechanism covering the risk mapping and trend analysis, risk exposure, potential impact and risk mitigation process is in place. The objective of the mechanism is to minimize the impact of risks identified and taking advance actions to mitigate it. The mechanism works on the principles of probability of occurrence and impact, if triggered. A detailed exercise is being carried out to identify, evaluate, monitor and manage both business and non-business risks.

Segment-Wise or Product-Wise Performance:

The Company's operation predominantly comprises of only one segment. In view of the same, separate segmental information is not required to be disclosed as per the requirement of Indian Accounting Standard 108 Operating Segment. Your company deals in various products such as Fungicides, herbicides, Weedicides, Insecticides and many more.

Discussion on Financial Performance with respect to Operational Performance:

(Amount in Lakhs)

PARTICULARS	F.Y. 2024-25	F.Y. 2023-24
Revenue From Operations	31,809.27	24,514.79
Other Income	45.36	18.04
Total Income	**31,854.63**	**24,532.83**
Less: Total Expenses Before Depreciation, Finance Cost and Tax	30,881.92	23,665.59
Profit Before Depreciation, Finance Cost and Tax	972.71	867.24
Less: Depreciation	260.24	157.07
Less: Finance Cost	165.77	169.41
Profit Before Tax	**546.69**	**540.76**
Less: Short Provision of Taxes in Earlier Year	-	0.31
Less: Current Tax	144.07	138.69
Less: Deferred Tax Liability (Liability)	(3.69)	12.19
Profit After Tax	**406.31**	**389.57**
Earning Per Share (Basic & Diluted)	5.97	5.72

Internal Control Systems and Their Adequacy:

The Company has established a comprehensive and adequate system of internal controls that is commensurate with the size and nature of its operations. These controls are designed to ensure the safeguarding of assets against unauthorized use or disposal, the accuracy and reliability of financial reporting, and compliance with applicable regulatory requirements and company policies. The Internal Audit Reports are regularly reviewed by the Audit Committee of the Board.

HUMAN RESOURCES AND INDUSTRIAL RELATIONS:

The Company believes that human resource is the most important assets of the organization. It is not shown in the corporate balance sheet, but influences appreciably the growth, progress, profits and the shareholders' values. During the year your company continued its efforts aimed at improving the HR policies and processes to enhance its performance. The vision and mission of the company is to create culture and value system and behavioral skills to insure achievement of its short- and long-term objectives. As on March 31, 2025, the Company had total 66 full time employees. The industrial relations have remained harmonious throughout the year.

DETAILS OF SIGNIFICANT CHANGES IN KEY FINANCIAL RATIOS, ALONG WITH DETAILED EXPLANATIONS THEREFOR:

RATIO	AS AT 31ST MARCH, 2025	AS AT 31ST MARCH, 2024	% OF CHANGE IN RATIO	EXPLANATIONS
Inventory Turnover	7.27	6.91	5%	Increase In Inventory
Interest Coverage Ratio	5.46	5.19	5%	Not Applicable
Current Ratio	6.74	7.46	-10%	Increase In Inventory and Trade Receivables
Debt Equity Ratio	0.59	0.62	-6%	Due To Decrease in Debt
Net Profit Margin/ Operating Profit Margin	0.0106	0.0148	-29%	Not Applicable
Return On Net Worth/ Return On Equity Ratio	0.11	0.12	-6%	Due to Increase in Turnover as well as Profit for the year
Debt Service Turnover Ration	0.42	0.38	9%	Due to Increase in Turnover as well as Profit for the year
Trade Receivable Turnover Ratio	5.60	4.80	16%	Company's Collection of accounts Receivable is Efficient
Trade Payable Turnover Ratio	8.71	10.36	-16%	Company Is Making Payments to Its Creditors on Time
Net Capital Turnover Ratio	5.23	4.30	22%	Company Is Being Very Efficient in Using a Company's Short-Term Assets and Liabilities for Supporting Sales
Return On Capital Employed	0.164	0.156	-6%	Not Applicable
Return On Investment	0.109	0.116	-6%	Not Applicable

Cautionary Note:

Statements in the Management Discussion and Analysis report may be 'forward looking statements' within the meaning of the applicable laws and regulations. Actual results may differ materially from those expressed or implied. Important factors that could make a difference to the Company's operations include among other, climatic conditions, economic conditions affecting demand, supply and price conditions in the domestic and overseas markets in which the Company operates, changes in the Government regulations, tax laws and other statutes and incidental.

For and on behalf of Board of Directors
Aristo Bio-Tech and Lifescience Limited
CIN: L01100GJ2005PLC127397

Registered office:
E-24/25/26, G.I.D.C., Ta. Savli,
Manjusar, Vadodara-391775,Gujarat

Place: Vadodara
Date: August 14, 2025

Narendra Singh Barhat
Chairman and Managing Director
DIN: 00310306

Ketankumar Harkantbhai Joshi
Whole Time Director & CFO
DIN: 02089127

ANNEXURE-D

SECRETARIAL AUDIT REPORT

FORM NO. MR-3

For the financial year ended March 31, 2025

[Pursuant to section 204(1) of the Companies Act, 2013 and

Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
Aristo Bio-Tech and Lifescience Limited
E-24, 25, 26, G.I.D.C. Manjusar, Ta. Savli ,
Vadodara -391775

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Aristo Bio-Tech and Lifescience Limited (hereinafter called 'the Company'). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/ statutory compliances and expressing my opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit. We hereby report that, in our opinion, the Company has, during the audit period covering the financial year ended on March 31, 2025, generally complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2025 according to the provisions of:

i. The Companies Act, 2013 ('the Act') and the rules made there under as applicable;

ii. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;

iii. The Depositories Act,1996 and the Regulations and Bye-laws framed there under;

iv. Foreign Exchange Management Act, 1999 (FEMA) and the rules and regulations made there under to the extent of Foreign Direct Investment;

v. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-

   a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and circulars/ guidelines/Amendments issued there under;

   b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and circulars/ guidelines/Amendments issued there under;

   c) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and circulars/ guidelines/Amendments issued there under;

   d) The Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

vi. Revised Secretarial Standards issued by the Institute of Company Secretaries of India.

Further company being engaged in the business of manufacturing of fertilizers, pesticides and other agro-chemical products, below are specific applicable laws to the Company, which require approvals or compliances under the respective laws;

1. The Explosives Rules, 2008
2. The Petroleum Act, 1934
3. The Pesticides Management Bill, 2020
4. The Insecticides (Price, Stock Display and Submission of Report) Order,1986;
5. The Insecticides Act, 1968 and the Insecticides Rules, 1971; and

We have relied on the representation made by the Company and its officers for system and mechanism framed by the Company for compliances of the aforesaid specific acts/rules/orders.

During the year under the report, the provisions of the Acts, Rules, Regulations, Guidelines, Standards, etc. mentioned above read with circulars, notifications and amended rules, regulations, standards etc. issued by the Ministry of Corporate Affairs, Securities and Exchange Board of India and such regulatory authorities for such acts, rules, regulations, standards etc. as may be applicable, from time to time issued for compliances, have been complied by the Company, Except:

SR. NO.	COMPLIANCE REQUIREMENT (REGULATIONS/ CIRCULARS / GUIDELINES INCLUDING SPECIFIC CLAUSE)	DEVIATIONS	OBSERVATIONS/ REMARKS OF THE PRACTICING COMPANY SECRETARY
1	Regulation 3(5) & 3(6) SEBI (Prohibition of Insider Trading) Regulations, 2015.	It was reported that the Company had delays in entering certain Unpublished Price Sensitive Information (UPSI) entries into the Structured Digital Database (SDD) software. Further, the flow of information related to some of these entries was found to be incorrect.	The Company has strengthened its internal processes for timely and accurate recording of UPSI in the SDD. Additionally, a clear accountability framework has been established to prevent recurrence of such lapses.

Further, Few ROC forms have been filed delayed with additional fees by the company for the financial year 2024-25

During the Period under review, provisions of the following Acts, Rules, Regulations, Guidelines, Standards, etc. were not applicable to the Company:

i. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client; - the Company is not registered as Registrar to an Issue & Share Transfer Agent.

   However, the Company has appointed MUFG Intime India Private Limited (earlier known as Link Intime India Private Limited) as Registrar & Share Transfer Agent as per the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

ii. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021;

iii. Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021;

iv. Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021;

v. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; and

vi. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and circulars/ guidelines/Amendments issued there under; and

vii. Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Overseas Direct Investment and External Commercial Borrowings.

We further report that -

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors, Independent Directors and Woman Director. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all Directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions of the Board and Committees were carried with requisite majority.

Since none of the members have communicated dissenting views in the matters / agenda proposed from time to time for consideration of the Board and Committees thereof, during the year under the report, hence were not required to be captured and recorded as part of the minutes.

We further report that –

There are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

There was no event/action which had major bearing on the Company's affairs in pursuance to the above referred laws, rules, regulations, guidelines, standards, etc.

For**, SCS and Co. LLP**
Company Secretaries
Firm Registration Number: - L2020GJ008700
Peer Review Number: - 5333/2023

SD/-

Anjali Sangtani
Partner
ACS No.: 41942 **C P No.:** 23630

UDIN: A041942G001014760

Date: August 14, 2025
Place: Ahmedabad

Note: This Report is to be read with my letter of above date which is annexed as Annexure I and forms an integral part of this report.

ANNEXURE I

To,
The Members,
Aristo Bio-Tech and Lifescience Limited
E-24, 25, 26, G.I.D.C. Manjusar, Ta. Savli ,
Vadodara -391775

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial records is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on my audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of secretarial records. The verification was done based on the records and documents provided to me, on test basis, to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices followed by me provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and books of accounts of the Company.
4. Wherever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provision of corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For**, SCS and Co. LLP**
Company Secretaries
Firm Registration Number: - L2020GJ008700
Peer Review Number: - 5333/2023

SD/-

Anjali Sangtani
Partner
ACS No.: 41942 **C P No.:** 23630

UDIN: A041942G001014760

Date: August 14, 2025
Place: Ahmedabad

INDEPENDENT AUDITOR'S REPORT

To
The Members of
M/S. ARISTO BIO-TECH AND LIFESCIENCE LIMITED
E-24/25/26, G.I.D.C, Manjusar,
Tal Savli, Dist. Vadodara, Gujarat, India – 391775

Report on the Audit of standalone Financial Statements

Opinion

We have audited the accompanying Standalone financial statements of **ARISTO BIO-TECH AND LIFESCIENCE LIMITED (*"the Company"*)** which comprises the Balance Sheet, the Statement of Profit and Loss, and statement of cash flows and notes to the financial statements for the year ended on March 31st, 2025, including a summary of significant accounting policies and other explanatory information (herein after referred as standalone financial statements).

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31st, 2025, and the profit, and its cash flows for the period ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on standalone financial statements except qualified opinion on the following.

Information Other than the Consolidated Financial Statements and Auditor's Report Thereon

The Company's Board of Directors are responsible for the preparation of other information. The other information comprises of the information included in the Board's Report including Annexure to Board's Report but does not include the standalone financial statements and the auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information, and in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, and cash flows of the Company in accordance with the accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance

with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SA's, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control. Under section 143 (i) of the Act, we are responsible for expressing our opinion on whether Company has adequate internal financial control system in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If, we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure, and content of the standalone financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company's to express an opinion on the standalone financial statements. We are responsible for the direction, supervision and performance of the Company's audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Other Matter

The figures in financial Statement for the half year and year ended on 31st March, 2025 and 31st March 2024 being the balancing figure between the audited figures in respect of the full financial year and published year to date figures up to the end of first half year of respected financial year. Also, the figures up to the end of the half year had only been reviewed and not subject to audit. Our report is not modified in respect of this matter.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, we report that:

   a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.

   b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

   c. The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.

   d. Except for the possible effects of the matter described in the Basis for Qualified Opinion paragraph, in our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

   e. On the basis of the written representations received from the directors as on March 31st, 2025 taken on record by the Board of Directors, none of the director is disqualified as on March 31st, 2025 from being appointed as a director in terms of Section 164 (2) of the Act

   f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "**Annexure A**".

   g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us

      i. The Company did not have any long-term contract including derivative contract for which there were any material foreseeable losses.

      ii. There were no amounts which were required to be transferred to the investment education and Protection fund by the company.

      iii. (a) The Management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

      (b) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in

any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

iv. As stated to the standalone financial statements

(a) The company was declared final dividend in the previous year, hence compliance as per Section 123 of the Act is applicable to the company. The company is complied with section 123 of the Act.

(b) The company was not declared any interim dividend and paid by the Company during the year and hence compliance as per Section 123 of the Act is not applicable to the company.

(c) The Board of Directors of the Company have proposed final dividend of Rs.0.50/- (par value of equity share of Rs.10 each) per equity share for the year which is subject to the approval of the members at the ensuing Annual General Meeting.

v. Based on our examination, which included test checks, the Company has used accounting softwares for maintaining its books of account for the financial year ended March 31, 2024 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with.

As proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable from April 1, 2023, reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 on preservation of audit trail as per the statutory requirements for record retention is not applicable for the financial year ended March 31, 2024.

2. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the "**Annexure B**" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

FOR PRAKASH CHANDRA JAIN & CO.
(Chartered Accountants)
Reg No. :002438C

CA DINESH C JAIN
Partner
B.Com. FCA, FAFD
M.No.: 041235
UDIN: 25041235BMFXXL2915

Date: 29/05/2025
Place: Vadodara

ANNEXURE A TO THE INDEPENDENT AUDITOR'S REPORT

(Referred in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirement's section our report to the Members of **ARISTO BIO-TECH AND LIFESCIENCE LIMITED)**

Report on the Internal Financial Controls under Clause (i) of sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act')

We have audited the internal financial controls over financial reporting of **ARISTO BIO-TECH AND LIFESCIENCE LIMITED** ('the Company') as of March 31st, 2025 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the 'Guidance Note') and the Standards on Auditing, issued by ICAI and deemed to be prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained are sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;

(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of the Management and directors of the Company; and

(3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31st, 2025, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

FOR PRAKASH CHANDRA JAIN & CO.
(Chartered Accountants)
Reg No. :002438C

CA DINESH C JAIN
Partner
B.Com. FCA, FAFD
M.No.: 041235

Date: 29/05/2025
Place: Vadodara
UDIN: 25041235BMFXXL2915

ANNEXURE "B" TO AUDITORS REPORT

(Referred in paragraph 2 under 'Report on Other Legal and Regulatory Requirement's section our report to the Members of **ARISTO BIO-TECH AND LIFESCIENCE LIMITED** of even date)

Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013.

Based on the audit procedures performed for the purpose of reporting a true and fair view on the financial statements of the Company and taking into consideration the information and explanations given to us and the books of account and other records examined by us in the normal course of audit, we report that:

i. (1)

a. The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.
b. The Company does not have any intangible assets hence requirement of this register not applicable.
c. The major Property, Plant and Equipment of the company have been physically verified by the management at reasonable intervals during the year and no material discrepancies were noticed on such verification.
d. According to the information and explanation given to us, the title deeds of the immovable properties (other than properties where the company is the lessee and the lease agreements are duly executed in favor of the lessee) are held in the name of the company.
e. The Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year.
f. According to the information and explanation given to us, no proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder during the year.

ii. (2)

a. The management has conducted physical verification of inventory at reasonable intervals during the year, in our opinion, the coverage and procedure of such verification by the management is appropriate. As informed to us, any discrepancies of 10% or more in the aggregate for each class of inventory were not noticed on such verification.

b. The company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets; Details of quarterly returns or statements filed by the company with such banks or financial institutions are as under:

Stock (Amount in Lakh)				
Quarter	Submitted to Bank	As per Books	Difference	% Variation
Q1	13560.48	13398.47	162.01	-1.21%
Q2	13223.82	13339.06	-115.75	-0.86%
Q3	13047.85	11544.07	1503.78	13.02%
Q4	15045.22	13282.33	1762.88	13.27%

iii. (3) The Company has made investments in, companies, firms, Limited Liability Partnerships, and granted unsecured loans to other parties, during the year, in respect of which:

a. during the year the company has not been provided loans or provided advances in the nature of loans, or stood guarantee, or provided security to any other entity
b. The Company has during the year, not made investments in, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties. Accordingly, the provisions of clauses 3(iii) of the Order are not applicable.

iv. (4) In our opinion and according to the information and explanations given to us, the Company has not directly or indirectly advanced loan to the persons covered under Section 185 of the Act or given guarantees or securities in connection with the loan taken by such persons and has complied with the provisions of section 186 of the Act, in respect of investments, loans, guarantee or security given, to the extent as applicable

v. (5) In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits from the public within the meaning of sections 73 to 76 of the Act and the Rules framed there under. Accordingly, paragraph 3(v) of the Order is not applicable to the Company.

vi. (6) As informed to us, the maintenance of Cost Records has been specified by the Central Government Under sub-section (1) of Section 148 of the Act, in respect of the activities carried on by the company. The cost auditor has carried out cost audit as per Companies Act and submitted its report up to March, 2024.

vii. (7) Based on the records examined by us and according to the information and explanations given to us, in respect of statutory dues:

(a) According to information and explanations given to us and on the basis of our examination of the books of account, and records, the Company has been generally regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Goods and Service tax, Cess and any other statutory dues with the appropriate authorities. According to the information and explanations given to us, no undisputed amounts payable in respect of the above were in arrears as at March 31st, 2025 for a period of more than six months from the date on when they become payable.
(b) Details of statutory dues referred to in sub-clause (a) above which have not been deposited
(c) as on March 31, 2025 on account of disputes are given below:

Name of the Statute	Nature of dues	Rs. in lakhs	Period to which amount relates	Forum where dispute is pending
Central Sales Tax Act, 1956	Sales Tax	18.22	FY 2017-18	Commissioner of Appeals

viii. (8) According to information and explanation given to us and representation given by the management, there were no transactions relating to previously unrecorded income that were surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

ix. (9)

a. In our opinion, the company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender during the year;
b. Company is not declared wilful defaulter by any bank or financial institution or other lender;
c. According to the information and explanation given to us, term loans were applied for the purpose for which the loans were obtained;
d. According to the information and explanation given to us, the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures;
e. According to the information and explanation given to us, the company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies;

x. (1)

a. During the year, the Company has not made any preferential allotment or private placement of Shares or convertible debentures (fully or partly or optionally) and hence reporting under clause 3(x)(b) of the Order is not applicable.

xi. (11)

a. According to the information and explanation given to us, any fraud by the company or any fraud on the company has not been noticed or reported during the year;

b. According to the information and explanation given to us, no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government;
c. According to the information and explanation given to us, no whistle-blower complaints, received during the year by the company;

xii. (12) Company is not a Nidhi company; accordingly, provisions of the Clause 3(xii) of the Order is not applicable to the company:

xiii. (13) In our opinion, the Company is in compliance with Section 177 and 188 of the Companies Act, 2013 with respect to applicable transactions with the related parties and the details of related party transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.

xiv. (14) In our opinion the Company has an adequate internal audit system commensurate with the size and the nature of its business.

xv. (16) According to the information and explanations given to us, we are of the opinion that the company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 and the company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India, accordingly the provisions of clause 3(xvi) of the Order are not applicable.

xvi. (17) The Company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.

xvii. (18) There has been no resignation of the statutory auditors during the year and accordingly, the provisions of clause 3(xviii) of the Order is not applicable.

xviii. (19) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that company is incapable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.

We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

xix. (20) According to the information and explanations given to us and on the basis of our examination of the records, provisions of Section 135 towards corporate social responsibility are not applicable on the company. Accordingly, the provision of clause 3(xx) of the Order is not applicable.

xx. (21) The reporting under clause (xxi) is not applicable in respect of audit of standalone financial statements of the Company. Accordingly, no comment has been included in respect of said clause under this report.

FOR PRAKASH CHANDRA JAIN & CO.
(Chartered Accountants)
Reg No. :002438C

CA DINESH C JAIN
(Partner)
B.Com. FCA, FAFD
M.No.: 041235
UDIN: 25041235BMFXXL2915

Date: 29/05/2025
Place: Vadodara

BALANCE SHEET AS AT 31/03/2025

(Amt. in Lakhs)

Sr. No.	PARTICULARS	Note No	31/03/2025	31/03/2024
(I)	***Equity And Liabilities***			
1	Share Holder's Funds			
	A) Share Capital	1	680.78	680.78
	B) Reserves and Surplus	2	3,052.35	2,680.08
	C) Money Received Against Share Warrents			
2	Share Application Money Pending Allotment			
3	Non-Current Liabilities			
	A) Long Term Borrowings	3	764.00	999.64
	B) Deferred Tax Liabilities (Net)	32	7.69	11.37
	C) Other Long-Term Liabilities	4	-	-
	D) Long Term Provision	5	-	-
4	Current Liabilities			
	A) Short Term Borrowings	6	1,421.43	1,087.95
	B) Trade Payable	7	-	-
	Total Outstanding Dues of Micro Enterprises and Small Enterprise		333.60	241.94
	Total Outstanding Dues of Creditors Other Than Micro Enterprises and Small Enterprise		7,507.03	6,707.92
	C) Other Current Liabilities	8	103.36	145.59
	D) Short-Term Provisions	9	192.16	173.42
	TOTAL		14,062.39	12,728.70
(II)	***Assets***			
1	NON-CURRENT ASSETS			
	A) Property, Plant & Equipment and Intangible Assets			
	(I) Tangible Assets	10	2,395.22	2,167.93
	(II) Intangible Assets	11	0.08	0.11
	(III) Capital Work-In-Progress	12	-	-
	(IV) Intangible Assets Under Development		-	-
	B) Non -Current Investments	13	-	-
	C) Deferred Tax Assets (Net)	32	-	-
	D) Long Term Loans and Advances	14	9.07	12.05
	E) Other Non-Current Assets	15	81.92	46.07
2	CURRENT ASSETS			
	A) Current Investments	16	-	-
	B) Inventories	17	4,736.57	4,018.66
	C) Trade Receivables	18	5,618.44	5,747.29
	D) Cash And Cash Equivalents	19	111.55	63.71
	E) Short Term Loans and Advances	20	1,047.35	630.98
	F) Other Current Assets	21	62.18	41.91
	TOTAL		14,062.39	12,728.70
(III)	***Contingent Liabilities***	31	18.22	47.86
See accompanying notes to the financial statements		33		
The Schedules referred to above form an integral part of the Balance Sheet				

As per our attached Report of even date

For, **Prakash Chandra Jain & Co.**
Chartered Accountants

For, **Aristo Bio-Tech and Lifescience Limited**

CA Dinesh C Jain
B.Com. FCA, FAFD
Membership No.: 041235
FRN No.:0002438C

Date: 29/05/2025
UDIN: 25041235BMFXXL2915

Narendra Singh Barhat
(Chairman & Managing Director)
(DIN-00310306**)**

Kusum Barhat
(Director)
(DIN: 00310065**)**

Ketan H Joshi
(CFO & Whole time Director)
(DIN: 02089127**)**

Diksha Peswani
(Company Secretary)
M No: ACS 76634

Place: Vadodara

Date: 29/05/2025

STATEMENT OF PROFIT AND LOSS ACCOUNT FOR THE PERIOD ENDING 31/03/2025

(Amt. in Lakhs)

Sr. No.	PARTICULARS	NOTE No	31/03/2025	31/03/2024
(I)	Revenue From Operations	22	31,809.27	24,514.79
(II)	Other Income	23	45.36	18.04
(III)	TOTAL REVENUE (I+II)		31,854.63	24,532.83
(IV)	*Expenses:*			
	Cost of Material Consumed	24	29,560.04	22,353.35
	Stores & Spares Consumed		-	-
	Purchases Of Stock-In-Trade	25	-	-
	Changes In Inventories of Finished Goods	26	-6.62	264.80
	Work In Progress and Stock-In-Trade		-	-
	Employee Benefits Expense	27	409.87	366.53
	Finance Cost	28	165.77	169.41
	Depreciation And Amortization Expense	10 & 11	260.24	157.07
	Other Expenses	29	918.63	680.90
	TOTAL EXPENSES		31,307.94	23,992.07
(V)	Profit Before Exceptional and Extraordinary Items and Tax (III-IV)		546.69	540.77
(VI)	*EXCEPTIONAL ITEMS:*	30		
	Prior Period Items (Net)			
	Other Exceptional Items			
(VII)	PROFIT BEFORE EXTRAORDINARY ITEMS AND TAX (V-VI)		546.69	540.77
(VIII)	Extraordinary Items			
(IX)	PROFIT BEFORE TAX (VII-VIII)		546.69	540.77
(X)	*Tax Expense:*			
	1) Short Provision of Taxes in Earlier Year		-	0.31
	2) Current Tax		144.07	138.69
	3) Deferred Tax	32	-3.69	12.19
(XI)	PROFIT/(LOSS)FOR THE PERIOD FROM CONTINUING OPERATIONS (IX-X)		406.31	389.57
(XII)	Profit/(Loss) From Discontinuing Operation		-	-
(XIII)	Tax Expense of Discontinuing Operation		-	-
(XIV)	PROFIT/(LOSS) FROM DISCONTINUING OPERATION (AFTER TAX) (XII-XIII)			
(XV)	PROFIT (LOSS) FOR THE PERIOD (XI-XIV)		406.31	389.57
(XVI)	Earnings per equity share:			
	1) Basic		5.97	5.72
	2) Diluted		5.97	5.72
See accompanying notes to the financial statements The Schedules referred to above form an integral part of the Balance Sheet				

As per our attached Report of even date

For, **Prakash Chandra Jain & Co.**
Chartered Accountants

For, **Aristo Bio-Tech and Lifescience Limited**

CA Dinesh C Jain
B.Com. FCA, FAFD
Membership No.: 041235
FRN No.:0002438C

Date: 29/05/2025
UDIN: 25041235BMFXXL2915

Narendra Singh Barhat
(Chairman & Managing Director)
(DIN-00310306**)**

Kusum Barhat
(Director)
(DIN: 00310065**)**

Ketan H Joshi
(CFO & Whole time Director)
(DIN: 02089127**)**

Diksha Peswani
(Company Secretary)
M No: ACS 76634

Place: Vadodara

Date: 29/05/2025

CASH FLOW STATEMENT AS ON 31ST MARCH 2025

Particular	F.Y. 2024-25		F.Y. 2023-24	
	Amount (In Lakhs)	Total Amount (In Lakhs)	Amount (In Lakhs)	Total Amount (In Lakhs)
Cash Flow from Operating Activity				
Net Profit Before taxation and extraordinary activities		546.69		540.77
Adjustment				
Depreciation	260.24		157.07	
Loss on sale of car	0.00		0.03	
Interest Income	-5.71		-4.61	
Expenses Reported under other activity head	165.77	420.31	169.41	321.91
Current Assets (other than cash)				
(Increase)/Decrease in Inventory	-717.91		-940.95	
(Increase)/Decrease in Trade Receivables	128.85		-1,289.98	
(Increase)/Decrease in other current assets	-20.27		-20.95	
(Increase)/Decrease in Short Term Loans and Advances	-416.37	-1025.70	-107.84	-2,359.72
Current liabilities				
Increase/(Decrease) in short term borrowing	333.47		-144.48	
Increase/(Decrease) in Other Current liabilities	-42.23		132.73	
Increase/(Decrease) in Trade payable	890.76		2,410.78	
Increase/(Decrease) In short Term Provision	18.74	1200.75	9.24	2,408.27
Cash Generated from operation		***1142.05***		***911.23***
less: Cash generated from discontinue business	-			
less: Income tax paid	-144.07		-138.69	
Add/(Less): DTA	3.69		-12.19	
Less: Short Provision in Last Year	0.00	-140.39	-0.31	-151.19
Net Cash flow from operating activities:		**1,001.67**		**760.04**
Cash flow from Investing Activities				
Increase Capital Work in Progress	-		-	
Purchase of Fixed Assets	-510.65		-655.49	
Sale of Fixed Assets	23.14		2.03	
Increase in other Non-current Assets	-35.86		-	
Increase in Long Term Loans & Advances	2.98		-12.10	
Increase in Non-Current Investment	-		-	
Purchase of Tangible Assets	-		-	
Interest Income	5.71		4.61	
Net Cash flow from Investing Activities:		**-514.68**		**-660.96**
Cash flow from Financing Activities				
Increase in share capital (IPO)	-		-	
Security Premium (IPO)	-		-	
IPO Expense	-		-	
Interest Expense	-180.92		-166.74	
Finance Cost	-8.84		-10.68	
Foreign Exchange (Loss)/gain	23.99		8.01	
Increase/(Decrease) In Long Term Borrowings	-235.64		-16.96	
Increase/(Decrease) In Deferred Tax Liability	-3.69		12.19	
Increase/(Decrease) In Other Long-Term Liability	0.00		-2.23	
Dividend paid	-34.04		-44.25	
Net Cash flow from Financing Activities:		**-439.14**		**-220.66**
Net Increase in Cash & cash Equivalent		**47.84**		**-121.58**
Cash & cash equivalent at beginning of period		**63.71**		**185.29**
Cash & cash equivalent at end of period		**111.55**		**63.71**

See accompanying notes to the financial statements
The Schedules referred to above form an integral part of the Balance Sheet

As per our attached Report of even date

For, **Prakash Chandra Jain & Co.**
Chartered Accountants

For, **Aristo Bio-Tech and Lifescience Limited**

CA Dinesh C Jain
B.Com. FCA, FAFD
Membership No.: 041235
FRN No.:0002438C

Date: 29/05/2025
UDIN: 25041235BMFXXL2915

Narendra Singh Barhat
(Chairman & Managing Director)
(DIN-00310306**)**

Kusum Barhat
(Director)
(DIN: 00310065**)**

Ketan H Joshi
(CFO & Whole time Director)
(DIN: 02089127**)**

Diksha Peswani
(Company Secretary)
M No: ACS 76634

Place: Vadodara **Date:** 29/05/2025

NOTES TO THE FINANCIAL STATEMENT FOR THE FINANCIAL YEAR ENDED MARCH 31, 2024

NOTE 1: SHARE CAPITAL:

(Amt. in Lakhs)

PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. 6(A) (a,b, & c) of Part I of Schedule III to the Companies Act, 2013		
Equity Share Capital		
Authorized:		
8,00,00,000 Equity shares of Rs. 10/- each	800.00	800.00
Paid up share Capital		
68,07,800 Equity shares of Rs. 10/- each	680.78	680.78
Issued, Subscribed & Fully Paid-up		
68,07,800 Equity Shares of Rs. 10 Each	680.78	680.78
Total	**680.78**	**680.78**

Reconciliation of the number of equity shares:		
PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note No. 6(A) (d) of Schedule III to the Companies Act,2013		
Shares outstanding at the beginning of the period	6,807,800	6,807,800
Addition:	-	-
Shares outstanding at the end of the period	6,807,800	6,807,800

Terms/Rights attached to Equity Shares
Disclosure pursuant to Note No. 6(A) (g) of Schedule III to the Companies Act,2013

List of shareholders holding more than 5% of total number of shares issued by the Company:

SR. NO.	NAME OF SHARE HOLDER	NO. OF SHARES HELD	% OF SHARES HELD	NO. OF SHARE HELD	% OF SHARES HELD
1	Narendra Singh Barhat	2,283,200	33.54	2,280,000	33.49
2	Ketan Joshi	720,000	10.58	720,000	10.58
3	Kusum Narendra Singh Barhat	625,000	9.18	625,000	9.18
4	Himanshu Barhat	515,000	7.56	515,000	7.56
5	Neeta K Joshi	480,000	7.05	480,000	7.05
	TOTAL	4,623,200	67.86	4,870,000	71.54

List of shares held by promoters at the end of the year:

SR. NO.	NAME OF SHARE HOLDER	NO. OF SHARES HELD BY PROMOTERS	% OF SHARES HELD	% CHNGE DURING THE YEAR	NO. OF SHARE HELD	% OF SHARES HELD
1	Narendra Singh Barhat	2,283,200	33.54	0.05%	2,280,000	33.49
2	Ketan Joshi	720,000	10.58	-	720,000	10.58
3	Kusum Narendra Singh Barhat	625,000	9.18	-	625,000	9.18
	TOTAL	36,28,200	53.30	0.05%	36,25,000	53.25

NOTE 2: RESERVES & SURPLUS

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. 6 (B) (i) of Part I of Schedule III to the Companies Act, 2013			
a	Share Premium Account	991.46	991.46
b	General Reserve	20.25	20.25
c	Reserve & Surplus	2,040.64	1,668.37
d	Balance In Profit & Loss Account	-	
	TOTAL	3,052.35	2,680.08

Disclosure pursuant to Note no. 6(B) of Part I of Schedule III to the Companies Act, 2013			
RESERVES & SURPLUS:			
SR NO.	PARTICULARS	31/03/2025	31/03/2024
a.	Share Premium Account		
	Opening Balance	991.46	991.46
Add:	Addition During the Current Year		-
Less:	IPO Cost ["See Note No. 44"]		-
	Closing Balance	991.46	991.46
b.	General Reserve		
	Opening Balance	20.25	20.25
Add:	Current Year Transfer		
Less:	Written Back In Current Year		
	Closing Balance	1,011.71	20.25
c.	Balance In Profit & Loss Account		
	Opening Balance	1,668.37	1,323.04
Add:	Net Profit/(Loss) For the Current Year	406.31	389.57
Less:	Dividend	34.04	
Add/Less:	Adjustment as per Companies Act 2013	-	
	Closing Balance	2,040.64	1,712.62
TOTAL		2,040.64	1,712.62

NOTE 3: LONG-TERM BORROWINGS:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
	Disclosure pursuant to Note no. 6(C) of Part I of Schedule III to the Companies Act, 2013		
1	**Secured:**		
a)	Term Loan from Bank (See Note No. 37)	739.97	890.17
	TOTAL	739.97	890.17
2	**Unsecured:**		
a)	From Related Parties	-	-
b)	From NBFC	-	-
c)	From Bank	-	-
d)	From Directors	24.03	109.47
		24.03	109.47
	TOTAL	764.00	999.64

1. *Term Loan form Bank of Baroda Secured by Hypothecation of Plant & Machinery & Factory Building.*
2. *Term Loan from SIDBI secured by Hypothecation of Plant & Machinery.*

NOTE 4: OTHER LONG-TERM LIABILITIES:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. 6 (D) of Part I of Schedule III to the Companies Act, 2013			
	Security Deposit from Customer	-	-
	TOTAL	-	-

NOTE 5: LONG-TERM PROVISIONS:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. 6 (E) of Part I of Schedule III to the Companies Act, 2013			
	TOTAL	-	-

NOTE 6: SHORT-TERM BORROWINGS:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
(I)	Secured Loans repayable on demand from banks (Cash Credit from Bank of Baroda Secured by Hypothecation) of Stock and Book Debts) (see note no-38)	1,066.50	785.13
(II)	Current Maturities of Long-Term Debts	354.93	302.82
	TOTAL	1,421.43	1,087.95

NOTE 7: TRADE PAYABLES:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
(I)	Sundry Creditors for Materials/ Supplies	7,700.04	6,886.44
(II)	Sundry Creditors for Capital Goods:	15.92	7.09
(III)	Sundry Creditors for Expenses:	124.68	56.34
	TOTAL	7,840.63	6,949.87
	Of the Above Total Outstanding Dues of Micro Enterprises and Small Enterprise	333.60	241.94
	Of the Above Total Outstanding Dues of Creditors Other Than Micro Enterprises and Small Enterprise	7,507.03	6,707.92

NOTE 8: OTHER CURRENT LIABILITIES:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. 6 (G) of Part I of Schedule III to the Companies Act, 2013			
(a)	Advance Received from Customer	59.27	107.95
(b)	Other Payables	34.04	27.23
(c)	Statutory Dues (On account of TDS, PF, ESIC & GST)	10.05	10.41
(e)	Salary Payable to Director	-	
	TOTAL	103.36	145.59

NOTE 9: SHORT-TERM PROVISIONS:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. 6 (H) of Part I of Schedule III to the Companies Act, 2013			
(a)	Provision for Employees' Benefits:	27.79	24.16
(b)	Others:		
	(I) Provisions Of Outstanding Liabilities for Purchase & Expenses:		
	Audit Fees Payable	7.96	6.83
	Provision for Expense	4.26	3.73
	Provision for CSR expenses	8.07	-
	(ii) Provision For Tax	144.07	138.69
	TOTAL	192.16	173.42

NOTE 10 & 11: FIXED ASSETS SCHEDULE 2024-25:

(Amt. in Lakhs)

TANGIBLE ASSETS

PARTICULARS	GROSS BLOCK				DEPRECIATION /AMORTIZATION				NET BLOCK	
NAME OF ASSET	As on 01.04.2024	Addition during the year	Deduction during the Year	As on 31.03.2025	Upto March 31.03.2024	During Period	Ded. During the Year	Upto 31.03.2025	As at 31.03.2025	As at March 31.03.2024
Air Conditioner	4.37	0.92	-	5.29	4.08	0.34	-	4.43	0.86	0.28
Factory Building	1,107.19	101.53	-	1,208.73	244.15	83.87	-	328.02	880.70	863.04
Lease Hold Factory Land	11.81	-	-	11.81	9.06	0.24	-	9.30	2.51	2.75
Computer And Data Processing Units	19.00	3.16	-	22.16	16.16	2.03	-	18.19	3.97	2.84
Electrical Installation And Equipment	65.08	32.92	-	98.01	31.45	14.31	-	45.77	52.24	33.63
Furniture & Fixtures	74.46	4.30	-	78.76	42.01	5.27	-	47.28	31.48	32.45
Intangible Assets	-	-	-	-	-	-	-	-	-	-
Lab Equipment	18.85	44.32	-	63.17	2.85	5.84	-	8.68	54.49	16.01
Motor Vehicle	121.59	51.68	53.80	119.47	81.24	14.23	30.66	64.81	54.66	40.35
Office Equipment	29.04	0.41	-	29.45	25.95	0.49	-	26.44	3.01	3.08
Plant And Machinery	1,016.97	271.41	-	1,288.38	394.05	133.60	-	527.65	760.73	622.92
Land And Flat	550.57	-	-	550.57	-	-	-	-	550.57	550.57
TOTAL:	3,018.94	510.65	53.80	3,475.79	851.02	260.22	30.66	1,080.58	2,395.22	2,167.93

INTANGIBLE ASSETS

PARTICULARS	GROSS BLOCK				DEPRECIATION /AMORTIZATION				NET BLOCK	
NAME OF ASSET	As on 01.04.2024	Addition during the year	Deduction during the Year	As on 31.03.2025	Upto March 31.03.2024	For the Year	Ded. During the Year	Upto 31.03.2025	As at 31.03.2025	As at March 31.03.2024
Intangible Assets	0.58	0.00	0.00	0.58	0.47	0.03	0.00	0.50	0.08	0.11
TOTAL	0.58	0.00	0.00	0.58	0.47	0.03	0.00	0.50	0.08	0.11

NOTE 12: CAPITAL WORK-IN-PROGRESS:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
	Opening Balance	-	-
	Less: - Depreciation	-	-
	Closing Balance	-	-
	TOTAL		

NOTE 13: NON-CURRENT INVESTMENT:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
	Disclosure pursuant to Note no. K (i) of Part I of Schedule III to the Companies Act, 2013	-	-
	TOTAL		

NOTE 14: LONG-TERM LOANS & ADVANCES:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. L (i), (ii),(iii) of Part I of Schedule III to the Companies Act, 2013			
I.	Capital Advances	9.07	12.05
II.	Loans and Advances - Other	-	-
	TOTAL	9.07	12.05

NOTE 15: OTHER NON-CURRENT ASSETS:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. M (i), (ii),(iii) of Part I of Schedule III to the Companies Act, 2013			
I.	Security Deposits	81.92	46.07
	TOTAL	81.92	46.07

NOTE 16: CURRENT INVESTMENTS:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
	TOTAL	-	-

NOTE 17: INVENTORIES:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. O (i), (ii) and (iii) of Part I of Schedule III to the Companies Act, 2013			
1	Raw-Materials and Components	4,621.50	3,910.21
2	Finished Goods (Closing stock value at a cost)	115.07	108.45
	TOTAL	4,736.57	4,018.66

NOTE 18: TRADE RECEIVABLES:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to note no. P(i),(ii),(iii) and (iv) of Part I of schedule III to the companies act, 2013			
1.	Unsecured (Considered Good)	5,425.00	5,544.68
2.	Unsecured (Considered Doubtful)	203.70	213.23
	Less: Provision for doubtful debts @5% ["See Note No. 45"]	(10.26)	(10.61)
	TOTAL	193.45	202.61
3.	Outstanding More Than Six Months	954.42	833.75

NOTE 19: CASH AND CASH EQUIVALENTS:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note No.6 (Q) (i), (ii), (iii), (iv) and (v) of Part I of Schedule III to the Companies Act, 2013			
A	Cash And Cash Equivalents:		
(a)	Balance With Bank	0.87	0.77
(b)	Cash On Hand	0.51	0.27
B	Other Bank Balances:		
	Fixed Deposits:	-	
	Fixed Deposits with Bank of Baroda	61.54	16.25
	Fixed Deposits with HDFC Bank	-	
	Fixed Deposits with SIDBI	46.12	43.92
	Deposits for Court Case as Guarantee ["See Note No. 47"]	2.50	2.50
	TOTAL	111.55	63.71

NOTE 20: SHORT-TERM LOANS & ADVANCES:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. R (i), (ii) and (iii) of Part I of Schedule III to the Companies Act, 2013			
I	Unsecured (Considered Good)		
(i)	Advance To Suppliers	506.32	14.38
(ii)	Advance To Employees	1.20	1.25
(iii)	Balance With Revenue Authorities Under Direct Taxes:	182.80	117.54
(v)	Advance To Director for Expenses	3.67	1.10
(vi)	**Balance With Revenue Authorities Under Indirect Taxes:**		
	Cash/ Credit Ledger Balance	318.17	477.55
	Refund claimed ["See Note No. 50"]	16.02 -	- -
	Deposits for Appeal (VAT) ("See Note No. 53")	19.16	19.16
	TOTAL	1,047.35	630.98

NOTE 21: OTHER CURRENT ASSETS:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. S of Part I of Schedule III to the Companies Act, 2013			
I.	IPO Deposits	1.00	1.00
II.	Other Current Assets	61.18	40.91
	TOTAL	62.18	41.91

NOTE 22: REVENUE FROM OPERATIONS:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note No. 2 A (a) of Part II of Schedule III to the Companies Act, 2013			
	Revenue Operations:		
	Sale - Export	489.53	793.07
	Sale - Local	30,940.30	23,579.09
	Sales - Service (Job Work Income)	379.17	140.64
	Consultancy Charges with GST	-	-
	Professional Fees for Obtaining License	-	-
	Duty Drawback Received	0.26	1.99
	Excise Duty drawback	-	-
	TOTAL	31,809.27	24,514.79

NOTE 23: OTHER INCOME:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. 4 of Part II of Schedule III to the Companies Act, 2013			
	Interest Income	1.42	0.86
	Interest received on Fixed Deposit with Bank	4.29	3.74
	Other Indirect Income	-	-
	Administrative Income Red.	-	-
	Cash Discount red	20.56	7.24
	Rate Difference Received	11.72	-
	Discount Difference	-	-
	Creditors Balance Write Off	-	6.19
	Profit on Sale of Car	6.87	-
	Bed debt recovery	0.51	-
	Trade Discount		-
	TOTAL	45.36	18.04

NOTE 24: COST OF MATERIAL CONSUMED:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. 5 (ii) 1 of Part II of Schedule III to the Companies Act, 2013			
	Opening Inventory of Raw Material	3,910.21	2,704.45
Add:	Purchase Of Raw Material	30,271.34	23,559.11
	Closing Inventory of Raw Material	4,621.50	3,910.21
	TOTAL	29,560.04	22,353.35

NOTE 25: PURCHASE OF STOCK-IN-TRADE:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. 5 (ii) 2 of Part II of Schedule III to the Companies Act, 2013			
	Purchases of Stock-In-Trade	-	-
	TOTAL	-	-

NOTE 26: CHANGE IN INVENTORIES OF FINISHED GOODS, PROCESS STOCK AND STOCK-IN-TRADE:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
1	Closing Stock:		
(a)	Finished Goods	115.07	108.45
(b)	Work-In-Progress	-	-
	SUB-TOTAL	**115.07**	**108.45**
Less:			
2	Opening Stock:		
(a)	Finished Goods	108.45	373.26
(b)	Work-In-Progress	-	-
	SUB-TOTAL	**108.45**	**373.26**

SR NO.	PARTICULARS	31/03/2025	31/03/2024
	TOTAL	-6.62	264.80

NOTE 27: EMPLOYEE BENEFIT EXPENSES:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. 5 (i) (a) of Part II of Schedule III to the Companies Act, 2013			
(a)	Salaries & Wages:	258.71	228.85
(b)	Contribution Towards PF	15.33	12.74
(c)	Staff Welfare Expense	6.74	9.05
(d)	Contribution Towards ESIC	1.25	1.75
(e)	Gratuity	2.60	0.38
(f)	Bonus	20.38	11.76
(g)	Insurance Paid for Worker	-	-
(h)	Leave Encashment	-	-
(i)	ESIC Charges	2.87	-
	TOTAL	308	264.53
(i)	Director's Remuneration	102.00	102.00
	TOTAL	409.87	366.53

NOTE 28: FINANCE COST

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. 3 (a), (b) and (c) of Part II of Schedule III to the Companies Act, 2013			
1	**Interest Expense:**		
a)	Interest On Term Loan	98.96	95.30
b)	Interest To Others	0.00	-
c)	Interest On Late Payment Of TDS, Custom Duty Etc	0.03	0.38
d)	Interest On Car Loan	3.63	2.38
e)	Interest On LC Discounting	-	-
f)	Interest On CC	96.82	93.91
g)	Interest On Income Tax	0.64	6.38
	Sub-total	200.08	198.34
	Less: Interest subsidy receivable (Refer note. No-52)	19.16	31.60
	TOTAL	180.92	166.74
2	**Other Borrowing Costs:**		
(i)	Bank Charges	8.01	10.68
(ii)	Processing Fees	0.83	-
(iii)	Loan Forclosure Charges		-
	TOTAL	8.84	10.68
3	**Gain or (Loss) Due to Foreign Exchange Transaction / Translation**	-23.99	-8.01
	("See Note No. 52")		
	TOTAL	165.77	169.41

NOTE 29: OTHER EXPENSES:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. 5 (vi) of Part II of Schedule III to the Companies Act, 2013			
	Direct Expenses		
	Export & Import Related Expense	30.26	20.28
	Job Work Expense Paid	-	1.17
	Freight Inward Expense	75.95	66.44
	Factory Expense	461.82	272.70
	Power & Fuel		
	Electricity Charges	0.14	0.16
	Electricity Charges – MFG.	40.07	22.15
	Fuel Exp- Diesel & Petrol	17.37	9.58
	Repair & Maintenance Expense		
	Repair & Maintenance Expense- Other	12.16	7.93
	Repair & Maintenance Expense- Plant & Machinery	17.64	19.25
	Repair & Maintenance Expense- Vehicle	1.71	4.59
	Other Expenses		
	Audit Fees	8.38	7.47
	AMC Charges	2.07	0.93
	Commission & Brokerage	5.55	1.33
	Computer Expense	0.23	0.06
	Director Sitting Fees	2.20	2.25
	Discount / Cash-Trade -Rebate Allowed	12.00	15.99
	Development Charges - GIDC	4.76	-
	Donation	-	0.15
	Designing Expense	-	0.88
	Exhibition & Stall Booking Charges	0.60	1.48
	Freight Outward Expense	40.54	72.43
	Govt Fees & License Fees	11.05	3.40
	Insurance Expense	22.58	17.72
	Loading & Unloading Expense	22.57	22.44
	Lodging & Boarding Expense	-	-
	Liquidated Damage Charges	-	0.16
	Listing fee	0.85	0.15
	Loss on sale of car	-	0.03
	Miscellaneous Expenses	5.25	0.51
	Membership fee	5.57	3.99
	Postage & Courier	1.55	0.84
	Printing & Stationary	2.95	4.83
	Professional Charges / Fees	58.63	54.07
	Professional Tax	0.02	0.02
	Rent	2.70	3.24
	Rounded Off	0.00	-0.00
	Rate Difference	-	2.86
	Sales / Business Promotion Expense	1.43	2.98
	Software Charges	0.17	0.48

SR NO.	PARTICULARS	31/03/2025	31/03/2024
	Telephone Expense	0.93	0.92
	Travelling & Conveyance	13.14	17.77
	VAT paid on assessment	0.21	-
	Office Expense	0.16	0.26
	Canteen Expense	11.76	10.48
	Balance Write Off	6.65	-
	GST Paid on Assessment	8.50	-
	GST Credit Disallowed	0.01	1.10
	Other Expenses (Reimbursement)	0.38	-6.07
	Provision for doubtful debts	-	10.61
	Gratuity	-	0.92
	CSR contribution	8.07	
	TOTAL	918.63	680.90

Note 30: PRIOR-PERIOD ADJUSTMENTS (NET):

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. 5 (i) (l) of Part II of Schedule III to the Companies Act, 2013			
Prior Period Expenses (Net)			
TOTAL		-	-

NOTE 31: CONTINGENT LIABILITIES:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
Disclosure pursuant to Note no. T of Part I of Schedule III to the Companies Act, 2013			
	Outstanding Tax Demand with Respect to Sales Tax AY 2014-15	-	-
	Outstanding Tax Demand with Respect to Sales Tax AY 2018-19	18.22	18.22
	Outstanding Tax demand in respect of GST for the period jan-17 to Jun-17	0.00	6.81
	Estimated number of contracts remaining to be executed and not provided for (See Note No. 34)	0.00	22.82
	TOTAL	18.22	47.86

Note 32: DEFERRED TAX LIABILITY/ ASSET:

(Amt. in Lakhs)

SR NO.	PARTICULARS	31/03/2025	31/03/2024
	Opening WDV as Per Income Tax Act, 1961	1,568.24	983.80
	Opening WDV as Per Books	1,614.72	1,008.29
	Net Difference -DTL	46.48	24.49
less:	Income Tax @25.16%	11.70	6.16
	Current Year Difference DTA	(15.94)	20.69
	Income Tax @25.16%	(4.01)	5.21
	Total Deferred Tax Liability (Assets)	-	11.37
	Amount Disallowed U/S 43 Of I T Act	-	-
	Income Tax @25.16%	-	-
	Unabsorbed Depreciation & Loss For The A.Y. 2020-21	-	-
	Income Tax @25.16%	-	-
	Net Deferred Tax Asset/(Liabilities)	-	11.37
less:	Already Provided	-	-0.81
	Provision Required	-3.69	12.19

Note 33: Schedule of notes forming part of Financial Statement:

COMPANY INFORMATION

Aristo Bio-Tech and Life science Limited ("the company") is a dedicated Crop Protection company providing Best Quality manufacturing, formulation, supply and packaging job work services for various Pesticides: Insecticides, Herbicides, Fungicides, Plant Growth Regulators and a wide variety of other Agrochemicals in India as well as for Export.

The company is a public limited company incorporated and domiciled in India and has its registered office at Manjusar, Vadodara, Gujarat, India. The Equity shares of the company are listed on National Stock Exchange of India Limited (SYMBOL/ISIN-ARISTO/INE082101010).

SIGNIFICANT ACCOUNTING POLICIES & NOTES TO THE ACCOUNTS

A. Basis of Preparation of Financial Statements

Financial statements have been prepared under the historical cost convention in accordance with the generally accepted accounting principles in India and the provisions of the Companies Act, 2013. The Company follows the mercantile system of accounting and recognizes income and expenditure on accrual basis except statutory claims/ refunds, which are accounted at the time of their admission by the concerned authorities.

B. Property, Plant and Equipment's (PPE)

Property, Plant and Equipments (PPE) PPE are recorded at cost of acquisition / construction less accumulated depreciation and impairment losses, if any. Cost comprises of the purchase price net of indirect taxes, if any, and any attributable cost of bringing the assets to its working condition for its intended use. Spare parts are treated as capital assets when they meet the definition of PPE. Otherwise, such items are classified as inventory. Any gains or losses on their disposal, determined by comparing sales proceeds with carrying amount, are recognized in the Statement of Profit or Loss.

C. Depreciation

Depreciation on fixed assets has been provided on Written down Method at the rates provided in part C of Schedule II of the Companies Act, 2013. Depreciation has been provided on Freehold land.

D. Foreign Currency Transaction

Foreign-currency-denominated monetary assets and liabilities are translated at exchange rates in effect at the Balance Sheet date. The gains or losses resulting from such translations are included in the statement of Profit and Loss.

Revenue, expenses and cash flow items denominated in foreign currencies are translated using the exchange rate in effect on the date of the transaction. Transaction gains or losses realized upon settlement of foreign currency transactions are included in determining net profit for the period in which the transaction is settled.

E. Investments

As such the company does not have any Items of Current investments, however if company has to maintain the same shall be carried at the lower of cost and quoted/fair value, computed category wise.

Company does not have any Items of Long-term investments, however if company has to maintain the same shall be carried at cost and provision for diminution in the value of long-term investments is made only if such a decline is other than temporary in the opinion of the management.

F. Inventories

Items of inventories are valued at lower of cost or net realizable value. Raw materials, stores and spare parts are valued at FIFO/weighted average basis. Cost of finished goods and stock in process is determined by taking material, labor and overheads.

G. Revenue Recognition:

Revenue is recognized based on nature of activity when consideration can be reasonably measured and there exists reasonable certainty of its recovery.

a) Sales of Goods & Services
b) Interest income is accrued at applicable interest rate.
c) Other items of income are accounted as and when the right to receive arises.

H. Employee Benefits:

I. Short term employee benefits:

All employee benefits falling due wholly within twelve months of rendering the service are classified as short-term employee benefits. The benefits like salaries, wages, short term compensated absences, etc are recognized in the period in which the employee renders the related service.

II. Retirement benefits:

The Company operates a defined contribution gratuity plan which requires contributions to be made to a separately administered fund by the Life Insurance Corporation of India (LIC). The cost of providing benefits under the defined benefit plan is determined using the projected unit credit method. The premium paid by the company is charged to the Statement of Profit and Loss.

Leave encashment is recorded in the books of the Company as and when the same arises and becomes payable. The Company does not make any provisions in the books of account for leave encashment becoming due or expected after the balance sheet date.

I. Provision for Current and Deferred Tax

Provision for current tax liability of the company is estimated considering the provisions of the Income Tax Act, 1961.

Deferred tax resulting from timing difference between book and taxable profit is accounted for using the tax rates and laws that have been enacted or substantively enacted on the balance sheet date. The deferred tax liability is recognized and carried forwarded.

J. Treatment of Contingent Liabilities

Provisions are recognized for liabilities that can be measured only by using a substantial degree of estimation, if

a) The company has a present obligation as a result of past event;

b) a probable outflow of resources is expected to settle the obligation; and

c) The amount of obligation can be reliably estimated.

Contingent liability is disclosed in case of

a) a present obligation arising from past events, when it is not probable that an outflow of resources will be required to settle the obligation;

b) a present obligation arising from past events, when no reliable estimate is possible; and

c) a possible obligation arising from past events where the probability of outflow of resources is not remote.

Contingent assets are neither recognize nor disclosed. Provisions, contingent liabilities and contingent assets are reviewed at each balance Sheet date.

K. Borrowing Cost:

A qualifying asset is an asset that requires a substantial period of time to get ready for its intended use. All other borrowing costs are recognized as an expense in the period in which they are incurred.

L. Impairment of Assets:

The Company assesses at each reporting date as to whether there is any indication that an asset (tangible and intangible) may be impaired. An asset is treated as impaired, when the carrying cost of the asset exceeds its recoverable amount. Recoverable amount is higher of an assets or cash generating unit's net selling price and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life.

An impairment loss is charged to Profit and Loss Account in the year in which an asset is identified as impaired. The impairment loss recognized in prior accounting period is reversed if there has been a change in the estimate of recoverable amount.

NOTE - 34 - CONTINGENT LIABILITIES:

(Rs. in Lakh)

SR NO.	PARTICULARS	AMOUNT
a.	Estimated number of contracts remaining to be executed and not provided for:	0.00
b.	Claims against the Company not acknowledged as debt:	Nil
c.	Bank Guarantees:	Nil
d.	Letters of credits outstanding:	Nil
e.	Outstanding Tax demand in respect of GST for the period jan-17 to Jun-17	6.81
f.	Outstanding Tax Demand with Respect to Sales Tax Assessment year - AY 2018-19	18.22

Claims against the Company for misbrand of Product under Insecticides Act, 1968.

(Rs. In Lakhs)

SR NO.	COURT CASES	AMOUNT	NATURE OF CASES
1	Punjab Khad Store - Jalandhar	Not known	Misbrand of Products (Insecticides Act, 1968)
2	Modern Fertilizer - Jalandhar	Not known	Misbrand of Products (Insecticides Act, 1968)
3	Mahabir Prasad Rajender Kumar- Jind	Not known	Misbrand of Products (Insecticides Act, 1968)

NOTE - 35 EARNINGS PER SHARE:

Basic Earnings Per share

PARTICULARS	FY 2024-25	FY 2023-24
Net Profit After Tax (Rs. in Lakh)	406.31	389.57
Weighted Average no. of Shares	68,07,800	68,07,800
Nominal Value Per share (Rs.)	Rs.10/-	Rs.10/-
Earnings Per share (Rs.)	5.97	5.72

NOTE - 36 INDIGENOUS AND IMPORTED RAW MATERIAL CONSUMED:

(Amount in Lakh)

SR. NO.	PARTICULAR	FY 2024-25	FY 2023-24
A	Imported (Including Custom Duty & other related charges)	2330.90	630.23
B	Indigenous	27940.44	22822.73
	Consumption	30271.34	23512.96

NOTE – 37: Terms of Repayment and Security Clause in respect of Long-term Borrowings:

- Term Loan outstanding amounting to Rs. 75.93 Lakhs (P.Y.106.29 Lakhs) from Small Industrial Bank of India is secured by hypothecation of Plant & Machinery, equipment's, spares, tools, accessories and other assets including movable assets acquired by using this loan and also secured by collateral security by lien on SIDBI fixed deposits of Rs.40.80 lakhs.

- Term Loan outstanding amounting to Rs. 174.02 Lakhs (P.Y.-nil) from Small Industrial Bank of India is secured by following:

  i) Hypothecation of Plant & Machinery, equipment's, spares, tools, accessories and other assets including movable assets acquired by using this loan.

  ii)-1) **Collateral securities are as under**: 1.) First charge on SIDBI the duly discharged Fixed deposit receipts [FDRs] issued by way of constructive delivery by SIDBI for an amount of Rs. 90.00 lakh (Rupees Ninety Lakh Only). The FDR should be taken in auto renewal mode and shall continue till the tenure of the loan. No premature withdrawal is permitted. The interest accrued on the FDRs shall not be payable periodically and the principal amount together with interest accrued thereon shall be payable on complete repayment of loan and all other monies payable under the Loan Agreement.

  2) Extension of first charge on SIDBI the duly discharged Fixed deposit receipts [FDRs] issued by way of constructive delivery by SIDBI for an amount of Rs. 40.80 lakh (Rupees Forty lakh Eighty Thousand Only). The FDR should be taken in auto renewal mode and shall continue till the tenure of the loan. No premature withdrawal is permitted. The interest accrued on the FDRs shall not be payable periodically and the principal amount together with interest accrued thereon shall be payable on complete repayment of loan and all other monies payable under the Loan Agreement.

  3) Extension of first charge by way of hypothecation in favour of SIDBI on the plant and machinery, equipment, spares, tools, accessories and all other assets including movable assets acquired / to be acquired under the earlier project of Rs 136.00 lakh.

  iii) Unconditional and Irrevocable guarantees of

- Shri Ketan Kumar Joshi
- Smt. Kusum Barhat
- Shri Narendra Singh Barhat

- The Vehicle Loans outstanding amounting to Rs.14.05 & Rs.21.92 Lakhs from Bank of Baroda are secured by hypothecation of vehicles.

- Term Loan outstanding amounting to Rs.674.88/-Lakhs (P.Y.-843.91 lakh) from Bank of Baroda is secured by following securities:
  i) equitable mortgage of factory land & building located at plot no E/24 & E/25 Savli Industrial estate and hypothecation of plant & Machinery, Furniture & Fixtures and other fixed assets proposed to be purchased out of bank finance.

The facilities as extended to the captioned company are secured by the following securities: -

1. Hypothecation of entire Raw Materials, stock-in-process, stores & spares, packing Materials, finished goods and book – debts of the company, both present & future primarily securing cash credit facility shall be extended to secure all other credit facilities too.

2. Hypothecation of plant & machineries.

3. Lien on FD of Rs. 1.31 crore

4. **Equitable mortgage of following securities**: -

   A. Leasehold industrial property situated at plot no. E/24 & E/25 in Savli industrial estate admeasuring 8000.00 sq. mtr. bearing R.S. No. 1723/P, 1724/P, 1739/P and 1740/P Mouje: Manjusar in the registration sub district, Savli and district Vadodara in the name of M/S Aristo bio – tech & Lifescience Limited.

   B. Leasehold industrial property situated at plot No. E – 26 in Savli industrial Estate admeasuring 4000.00 sq. mtr. bearing R.S. No. 1723/P & 1724/P , 1739/P and 1740/P part Paiki Mouje : Manjusar in the registration sub district, Savli and district Vadodara belonging of M/S Aristo bio – tech & life science PVT Ltd.

   C. Freehold industrial land at block No. 165/A/P1/1 bearing old survey No. 353,354 &355 in Mouje: Alindra in the registration sub district , Savli and district Vadodara. the said property admeasuring about 19712.00 sq. Mrts. belonging to M/S Aristo bio – tech & life science PVT Ltd.

   D. Residential flat no. A 201, 2nd floor , admeasuring 120.77 sq. Mtrs. Situated in North – West direction of A – tower of Nakshatra Heights with proportionate share of 75.48 sq. mtr. Paikee 2127 sq. mtr. FP NO .145 , VUDA T.P. No.1 in registration sub – district Vadodara and district Vadodara belonging to Mr. Narendra Singh Barhat & Mrs. Kusum Narendra singh Barhat.

   E. Residential Flat No. 101, 1nd floor, Paiki tower – O of scheme – Shravan paradise admeasuring 111.00 sq. mtrs with undivided land for common road and common plot at Block no. 1770 adm. 11510 sq. mtr. Old RS No. 2475 & 2477/2 of registration sub – district Savli and district Vadodara belonging to M/S Aristo Bio – tech & Lifescience Private limited.

5. Personal Guarantee of the following individual for all above mentioned credit facilities except AWCTL under BGECLS:-

Mrs. Kusum Barhat	Director
Mr. Narendra Singh Barhat	Managing Director
Mr. Ketankumar Harkantbhai Joshi	Director

- The Company had been sanctioned the Working Capital Demand Loan (WCDL) amounting to Rs. 168.00 Lakhs (P.Y. NIL) from Bank of Baroda. Security clause in respect of said Overdraft Facility are as follows:
  i) No additional collateral shall be insisted by bank for additional credit extended under this scheme.

  ii) However, credit under this scheme will rank second charge with existing credit facilities (as stipulated in respective of guideline o BGECL 1.0 in terms of cash flow (including repayments) and securities charged to existing facilities.

Note -38:

The company had been sanctioned credit facilities with Bank of Baroda and secured by hypothecation of entire current assets of the company. E.g. Raw Material, Stock in process, semi-finished goods, stores, spares, & book debt both present & future.

Note -39: Payment to Auditors:

(Rs. In Lakh)

Particulars	2024-25	2023-24
Statutory Audit Fees	7.00	6.00
Total	**7.00**	**6.00**

Note- 40: The Deferred Tax liability as at 31st March, 2025 comprise of the following:

(Rs. In Lakh)

PARTICULARS	FY 2024-25	FY 2023-24
WDV as per Books	1568.24	1008.29
WDV as per IT	1614.72	983.80
Time Difference	46.48	24.49
Tax Rate	25.17%	25.17%
A. Deferred Tax Asset/(Liability)	11.70	6.16
Current Year Difference	(15.94)	(20.69)
B. Deferred Tax Asset/(Liability)	(4.01)	5.21
Deferred Tax Asset/(Liabilities) (Net) as at the Closing of the year (A+ B)	**7.69**	**(11.37)**
Deferred Tax Asset/(Liabilities) (Net) as at the beginning of the year	(11.37)	(0.81)
Deferred Tax Income/(Expense) to be recognized in the P&L this year	**(3.68)**	**(12.19)**

Deferred tax liability on opening WDV has been charged to the profit and loss appropriation account, whereas the current deferred tax liability has been charged to profit and loss account.

NOTE - 41 -Expenditure in Foreign Currency for traveling: Rs. 3.71/-Lakhs

NOTE - 42 -Earnings in foreign currency Rs. 279.88/- Lakhs

NOTE - 43 -Remittances in foreign currency Rs. 2130.49/- Lakhs

NOTE - 44:

Inter Branch sale and purchase transactions are treated as supply as per GST Law while as per general accounting norms Interbranch transactions are branch transfer hence inter branch sales and purchases are excluded from overall sales and purchases for the year.

NOTE - 45:

With regard to the creditors appearing in the balance sheet, it is hereby stated that the details as to which creditors are classified as Micro, Small or Medium Enterprises as per the MSME Act were available with the company, so the creditors are shown in totality in the financial statements and even the interest on delayed payment to MSME's as per the government regulations, if any, is thus known and is provided in the books of accounts.

(Amount in Lakhs)

SR. NO.	PARTICULARS	MARCH 31, 2025	MARCH 31, 2024
a)	Principal amount and the interest due thereon remaining unpaid to each supplier at the end of each accounting year (but within due date as per the MSMED Act)	--	--
	Principal amount due to micro and small enterprise	333.60	241.94
	Interest due on above	--	--
b)	Interest paid by the Company in terms of Section 16 of the Micro, Small and Medium Enterprises Development Act, 2006, along with the amount of the payment made to the supplier beyond the appointed day during the period	--	--
c)	Interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the period) but without adding interest specified under the Micro, Small and Medium Enterprises Development Act, 2006	--	--
d)	The amount of interest accrued and remaining unpaid at the end of each accounting year	--	--
e)	Interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprises	--	--

NOTE - 46 - NOTE ON TREATMENT OF INITIAL PUBLIC ISSUE EXPENSES (SHARE ISSUE EXPENSES):

The company has adjusted share issue expenses against security premium received on Initial Public offer (IPO).

NOTE - 47 - NOTE ON TRADE RECEIVABLE POLICY:

A Provision for doubtful debt is recognized for all the trade receivable (non-government) outstanding for more than 3 years at the rate of 5% on the outstanding amount as on 31st March, 2025.

Trade Receivables Outstanding for more than 3 Years	5% Provision for Bad debts
203.70	10.26

NOTE – 48:

During the year, the company has deposited Rs. 0.50 Lakh as guarantee deposit for court case ongoing on company for misbrand of product and the deposit is considered under deposits. (Reference note no. 34)

NOTE – 49

The company has recognized deposit received from dealer as long-term deposits under other long-term liabilities.

NOTE - 50: NOTE ON GST

Balance shown in Cash/Credit Ledger (GST Input and GST Output account) under the head Loans & Advances may not necessarily reconcile with the GSTR-3B, GSTR 1 and GSTR 2A returns filled by the Company and the Suppliers of the Company. The same are subject to reconciliation and rectification, whenever necessary and shall be finalized at the time of filling GST Annual Return by the Company. The current GST Input credit/GST output liabilities are stated based on the books of accounts maintained by the Company. Financial Impact on account of such reconciliation/rectification shall be quantified and accounted for only at the time of the GST Annual return GSTR-9 of the Company.

NOTE – 51:

The Company has made Direct Export i.e., Bill to ship to model in which the goods are not physically arrived in Indian territory and directly transferred to buyer's county from sellers' country, this transaction is not covered under supply definition under section 7 of Goods and Service Tax Act, 2017 and the same has been not considered under GST Turnover for the year.

NOTE - 52:

Interest Subsidy receivable: - The Industry Policy 2020 scheme for assistance to Micro, Small & Medium Enterprise interest subsidy scheme, has become operational since 07/08/2020. The scheme has been introduced by the Government of Gujarat to facilitate ease of doing business for the MSME sector in state of Gujarat. This scheme provides assistance for interest subsidy @ 5% on term loan with maximum amount of ₹ 25 lakhs per annum for a period of 5 years, the company after receiving the formal sanction from the Competent authorities have calculated eligible interest subsidy receivable for the interest paid and the same is accounted for the year under the head Interest subsidy receivables account.

NOTE - 53 - RELATED PARTY DISCLOSURES:

i. Key Managerial Person:

SR.	NAME	DESIGNATION
1.	Mr. Narendra Singh Barhat	(Chairperson and Managing Director)
2.	Mr. Ketankumar Harkantbhai Joshi	(Whole Time Director & CFO)
3.	Mrs. Ayushi Deora	(Company Secretary)
4.	Mrs. Kusum N. Barhat	(Executive Director)
5.	Mr. Raghavender Mateti	(Independent Director)
6.	Ms. Rashmi Kamlesh Otavani	(Independent Director)
7.	Mr. Laxman Singh Rathore	(Non-executive Director)

ii. Associates:

1. Orchid Agro System
2. Kinlak Biotech
3. Indus Findem LLP

iii. Relatives of Director:

4. Himanshu Barhat
5. Richa Barhat

iv. Related Entities:

6. Narendra Singh Barhat HUF (Directors is Karta in HUF)

(Amount in Lakh)

SR. NO	NATURE OF TRANSACTIONS	SUBSIDIARIES/ BENEFICIARY	ASSOCIATES	KEY MANAGERIAL PERSONNEL/ RELATIVE	CONTROLLING INTEREST	TOTAL
1	Directors' Remuneration	-	-	102.00	-	102.00
2	Director Sitting Fees	-	-	2.20	-	2.25
2	Loan Accepted	-	-	-	-	-
3	Loan Repaid	-	85.43	-	-	85.43
4	Sales	-	969.67		-	969.67
5	Loan advanced	-	-	-	-	-
6	Rent paid			2.40		2.40
7	Purchase		492.29	-	-	492.29
8	Salary			29.35		29.35
	Total:		1547.39	135.95		1683.34

v. Transaction carried out with related parties referred in a. above, in ordinary course of business:

(AMT. IN LAKHS)

NATURE OF TRANSACTION	NAME OF RELATED PARTY	AMOUNT PAID
Directors' Remuneration	Mr. Narendra Singh Barhat	36.099
	Mrs. Kusum N. Barhat	22.068
	Mr. Ketankumar Harkantbhai Joshi	22.047
Director Sitting Fees	Raghvedra Mateti	1.08
	Rashmi Kamlesh Otavani	1.12
Rent Paid	Mrs. Kusum N. Barhat	2.40
Salary	Himanshu Barhat	15.19
	Richa Barhat	11.76
Sales	Orchid Agro System	558.05
Sales	Kinlak Biotech	87.82
Sales	Indus Finchem LLP	323.79
Purchase	Orchid Agro System	151.29
Purchase	Indus Finchem LLP	340.99
Loan Repaid		
	Narendra Singh Barhat	53.43
	Kusum Barhat	12.00
	Ketan Joshi	20.00

NOTE - 54: TRADE RECEIVABLE AGEING REPORT

Current year as on 31/03/2025							
PARTICULAR		LESS THAN 6 MONTHS	MORE THAN 6 MONTHS	1-2 YEARS	2-3 YEARS	MORE THAN 3 YEARS	TOTAL
Unsecured, Considered good, Undisputed	Non-Government	4531.26561	437.783	205.757	48.23656	136.55	5359.5929
	Government	132.761666	58.3109	7.91577	1.53213	58.33	258.850465

Previous year as on 31/03/2024							
Particular		Less than 6 months	More than 6 months	1-2 years	2-3 years	More than 3 Years	Total
Unsecured, Considered good, Undisputed	Non-Government	4723.29803	603.333	88.1614	0	202.613	5617.40534
	Government	98.6179	26.7823	2.10729	2.37787	0	129.88537

NOTE 55: TRADE PAYABLE AGEING REPORT:

Current year as on 31/03/2025					
PARTICULAR	LESS THAN 1 YEAR	1-2 YEARS	2-3 YEARS	MORE THAN 3 YEARS	TOTAL
MSME	333.6013	0	0	0	333.6013
Others	7348.2687	157.21	0.45	1.09	7507.019

Previous year as on 31/03/2024					
PARTICULAR	LESS THAN 1 YEAR	1-2 YEARS	2-3 YEARS	MORE THAN 3 YEARS	TOTAL
MSME	241.94344	0	0	0	241.9434
Others	6705.85929	2.06497	0	0	6707.924

NOTE - 56: RATIO

RATIO	AS AT 31ST MARCH, 2025	AS AT 31ST MARCH, 2024	% OF CHANGE IN RATIO	EXPLANATIONS
Inventory Turnover	7.27	6.91	5%	Increase In Inventory
Interest Coverage Ratio	5.46	5.19	5%	Not Applicable
Current Ratio	6.74	7.46	-10%	Increase In Inventory and Trade Receivables
Debt Equity Ratio	0.59	0.62	-6%	Due To Decrease in Debt
Net Profit Margin/ Operating Profit Margin	0.0106	0.0148	-29%	Not Applicable
Return On Net Worth/ Return On Equity Ratio	0.11	0.12	-6%	Due to Increase in Turnover as well as Profit for the year
Debt Service Turnover Ration	0.42	0.38	9%	Due to Increase in Turnover as well as Profit for the year
Trade Receivable Turnover Ratio	5.60	4.80	16%	Company's Collection of accounts Receivable is Efficient
Trade Payable Turnover Ratio	8.71	10.36	-16%	Company Is Making Payments to Its Creditors on Time
Net Capital Turnover Ratio	5.23	4.30	22%	Company Is Being Very Efficient in Using a Company's Short-Term Assets and Liabilities for Supporting Sales
Return On Capital Employed	0.164	0.156	-6%	Not Applicable
Return On Investment	0.109	0.116	-6%	Not Applicable

NOTE - 57:

Previous year's figures have been regrouped / reclassified, where necessary, to confirm to current year's presentation.

NOTE - 58: Corporate social responsibility (CSR):

The Company had provisioned Rs. 8.07 Lakh towards CSR based on profits calculated under Section 198 of the Companies Act, 2013 by March 31, 2025. However, based on a legal opinion obtained post completion of FY 2024–25, since the Profit After Tax (PAT) for FY 2023–24 did not exceed Rs. 5 crores, the Company is not mandatorily required to spend on CSR under Section 135(1) in FY 2024–25.

The Company intends to incur the CSR expenditure relating to this provision in FY 2025–26. As CSR is not applicable for FY 2024–25, the amount will be adjusted against CSR liability in subsequent years in accordance with Rule 7(1)(b) of the Companies (Corporate Social Responsibility Policy) Rules, 2014, and Section 135 of the Companies Act, 2013.

For, **Prakash Chandra Jain & Co.**
Chartered Accountants

For, **Aristo Bio-Tech and Lifescience Limited**

CA Dinesh C Jain
B.Com. FCA, FAFD
Membership No.: 041235
FRN No.:0002438C

Date: 29/05/2025
UDIN: 25041235BMFXXL2915

Narendra Singh Barhat
(Chairman & Managing Director)
(DIN-00310306**)**

Ketan H Joshi
(CFO & Whole time Director)
(DIN: 02089127**)**

Kusum Barhat
(Director)
(DIN: 00310065**)**

Diksha Peswani
(Company Secretary)
M No: ACS 76634

Place: Vadodara

Date: 29/05/2025

NOTICE OF THE 20TH ANNUAL GENERAL MEETING

NOTICE is hereby given that the Twentieth (20th) Annual General Meeting (AGM) of the Members of Aristo Bio-Tech and Lifescience Limited will be held on Monday, September 08, 2025 at 03:00 P.M. IST through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") to transact the following businesses;

The venue of the meeting shall be deemed to be the Registered Office of the Company at E-24,25,26, G.I.D.C. Manjusar, Ta. Savli, Vadodara -391 775.

ORDINARY BUSINESSES:

1. TO ADOPT FINANCIAL STATEMENTS:

To consider and adopt the audited standalone financial statement of the Company for the financial year ended March 31, 2025 and the reports of the Board of Directors and Auditors thereon; in this regard, to consider and if thought fit, to pass, with or without modification(s), the following resolutions as an **Ordinary Resolution**.

"**RESOLVED THAT**, the audited standalone financial statement of the Company for the financial year ended March 31, 2025 and the reports of the Board of Directors and Auditors thereon, as circulated to the members, be and are hereby considered and adopted."

2. TO APPOINT A DIRECTOR IN PLACE OF MR. LAXMAN SINGH RATHORE (DIN: 08218555), AS NON-EXECUTIVE DIRECTOR WHO RETIRES BY ROTATION AND BEING ELIGIBLE, OFFERS HIMSELF FOR RE-APPOINTMENT:

Explanation: Based on the terms of appointment, Executive Directors and the Non-Executive Directors (other than Independent Directors) are subject to retirement by rotation. Mr. Laxman Singh Rathore (DIN: 08218555),Non-Executive Director who has been on the Board of the Company since March 20, 2022 and whose office is liable to retire at this AGM, being eligible, seeks re-appointment. Based on the performance evaluation and the recommendation of the Nomination and Remuneration Committee, the Board recommends his re-appointment.

Therefore, the shareholders are requested to consider and, if thought fit, to pass with or without modification(s), the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT pursuant to the provisions of Section 152 and other applicable provisions of the Companies Act, 2013, Mr. Laxman Singh Rathore (DIN: 08218555), who retires by rotation, be and is hereby re-appointed as Non Executive Director, liable to retire by rotation."

3. TO DECLARE FINAL DIVIDEND:

To declare a final dividend of ₹0.50 per share (Rupees Fifty Paisa only) per Equity share of Rs. 10/- each for the financial year ended on March 31, 2025.

4. TO RE-APPOINT M/S PRAKASH CHANDRA JAIN & CO., CHARTERED ACCOUNTANTS (FRN: 002438C) AS STATUTORY AUDITORS OF THE COMPANY FOR SECOND TERM OF FOUR YEARS:

To consider and if thought fit to pass with or without modifications the following resolution as an **Ordinary Resolution**:

"**RESOLVED THAT** pursuant to the provisions of Section 139, 141, 142 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 and applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force) and pursuant to the recommendation of the Audit Committee, M/s. Prakash Chandra Jain & Co., Chartered Accountants (FRN: 002438C) be and are hereby re-appointed as Statutory Auditors of the Company for a second term of four consecutive years to hold office from the conclusion of 20th Annual General Meeting till the conclusion of 24th Annual General Meeting at such remuneration as may be recommended by the Audit Committee and determined by the Board of Directors in consultation with the Statutory Auditors.

RESOLVED FURTHER THAT the Board of Directors of the Company, (including its committees thereof), be and are hereby authorized to do all such acts, deeds, matters and things as may be deemed proper, necessary, or expedient, including filing the requisite forms or submission of documents with any authority or accepting any modifications to the clauses as required by such authorities, for the purpose of giving effect to this resolution and for matters connected therewith, or incidental thereto."

SPECIAL BUSINESS:

5. TO RATIFY THE REMUNERATION PAYABLE TO THE COST AUDITORS FOR THE FINANCIAL YEAR 2025- 2026

To Consider and if thought fit, passed the following resolution with or without modification(s), as an **Ordinary Resolution**:

"**RESOLVED THAT** pursuant to the provisions of Section 148 read with Companies (Audit and Auditors) Rules, 2014, and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory amendment(s)/modification(s) thereof for the time being in force), the Members be and hereby approve and ratify the remuneration of INR 64,900/- (Rupees Sixty Four Thousand Nine Hundred Only) excluding out of pocket expenses & taxes as applicable to M/s. YS Thakar & Co, Cost Accountants (Firm Registration No.: 000318) who were appointed as Cost Auditors of the Company by the Board of Directors on the recommendation of the Audit Committee to conduct audit of cost accounting records for the financial year 2025-2026.

RESOLVED FURTHER THAT the Board of Directors of the Company, (including its committees thereof), be and are hereby authorized to do all such acts, deeds, matters and things as may be deemed proper, necessary, or expedient, including filing the requisite forms or submission of documents with any authority or accepting any modifications to the clauses as required by such authorities, for the purpose of giving effect to this resolution and for matters connected therewith, or incidental thereto."

6. TO APPROVE REVISION IN REMUNERATION PAYABLE TO MR. NARENDRA SINGH BARHAT (DIN: 00310306), CHAIRMAN AND MANAGING DIRECTOR OF THE COMPANY:

To consider and if thought fit, to pass with or without modification(s), the following resolution as a **Special Resolution:**

"**RESOLVED THAT**, pursuant to the provisions of Section 196, 197, 198, 203 and other applicable provisions of the Companies Act, 2013, and Schedule V to the Act read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and other applicable rules, regulations issued by the Ministry of Corporate Affairs in this regard including any statutory amendments, modifications or re-enactment thereof and all other statutory approvals, as may be required and on recommendation of Nomination and Remuneration Committee and pursuant to approval of the Board of Directors (hereinafter referred to as "the Board"), the approval of the Members of the Company be and is hereby accorded for revision in remuneration and perquisites (hereinafter referred to as "remuneration") payable to Mr. Narendra Singh Barhat (DIN: 00310306) as Chairman and Managing Director of the Company as set out in the explanatory statement attached hereto with effect from September 01, 2025, for his existing remaining term until revised further with other terms and conditions remaining unchanged with the power to the Board of Directors to alter and modify the same, as per the provisions of the Act and in the best interest of the Company.

RESOLVED FURTHER THAT, subject to the provisions of Section 197 of the Companies Act, 2013 as amended from time and time, the Remuneration payable to Mr. Narendra Singh Barhat (DIN: 00310306) as set out in the explanatory statement attached hereto, in the event of loss or inadequacy of profit in any Financial Year, shall be as per the limit set out in Section II of Part II of Schedule V to the Companies Act, 2013.

RESOLVED FURTHER THAT for the purpose of giving effect to this Resolution, the Board of Directors (or any Committee thereof) be and is hereby authorized to undertake all acts, deeds and execute all documents and pass relevant resolutions for the purpose of giving effect to this resolution, including modification and amendment of any revisions, thereof and to enter into relevant agreement with the Director, as required, from time to time and to undertake all such steps, as may be deemed necessary in this matter.

RESOLVED FURTHER THAT the Board of Directors and/or the Company Secretary of the Company, either jointly or severally be and are hereby authorized to file the said resolution with the Registrar of Companies, and to do all such acts, deeds and things as may be necessary, expedient and incidental thereto to give effect to the above resolution."

7. TO APPROVE REVISION IN REMUNERATION PAYABLE TO MRS. KUSUM NARENDRA SINGH BARHAT (DIN: 00310065), EXECUTIVE DIRECTOR OF THE COMPANY:

To consider and if thought fit, to pass with or without modification(s), the following resolution as a **Special Resolution**:

"**RESOLVED THAT**, pursuant to the provisions of Section 197, 198 and other applicable provisions of the Companies Act, 2013, and Schedule V to the Act read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and other applicable rules, regulations issued by the Ministry of Corporate Affairs in this regard including any statutory amendments, modifications or re-enactment thereof and all other statutory approvals, as may be required and on recommendation of Nomination and Remuneration Committee and pursuant to approval of the Board of Directors (hereinafter referred to as "the Board"), the approval of the Members of the Company be and is hereby accorded for revision in remuneration and perquisites (hereinafter referred to as "remuneration") payable to Mrs. Kusum Narendra Singh Barhat (DIN: 00310065) as Executive Director of the Company as set out in the explanatory statement attached hereto with effect from September 01, 2025, for her existing remaining term until revised further with other terms and conditions remaining unchanged with the power to the Board of Directors to alter and modify the same, as per the provisions of the Act and in the best interest of the Company.

RESOLVED FURTHER THAT, subject to the provisions of Section 197 of the Companies Act, 2013 as amended from time and time, the Remuneration payable to Mrs. Kusum Narendra Singh Barhat (DIN: 00310065) as set out in the explanatory statement attached hereto, in the event of loss or inadequacy of profit in any Financial Year, shall be as per the limit set out in Section II of Part II of Schedule V to the Companies Act, 2013.

RESOLVED FURTHER THAT for the purpose of giving effect to this Resolution, the Board of Directors (or any Committee thereof) be and is hereby authorized to undertake all acts, deeds and execute all documents and pass relevant resolutions for the purpose of giving effect to this resolution, including modification and amendment of any revisions, thereof and to enter into relevant agreement with the Director, as required, from time to time and to undertake all such steps, as may be deemed necessary in this matter.

RESOLVED FURTHER THAT the Board of Directors and/or the Company Secretary of the Company, either jointly or severally be and are hereby authorized to file the said resolution with the Registrar of Companies, and to do all such acts, deeds and things as may be necessary, expedient and incidental thereto to give effect to the above resolution."

8. TO APPROVE REVISION IN REMUNERATION PAYABLE MR. KETANKUMAR HARKANTBHAI JOSHI (DIN: 02089127), WHOLE TIME DIRECTOR OF THE COMPANY:

To consider and if thought fit, to pass with or without modification(s), the following resolution as a **Special Resolution**:

"**RESOLVED THAT**, pursuant to the provisions of Section 196, 197, 198, 203 and other applicable provisions of the Companies Act, 2013, and Schedule V to the Act read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and other applicable rules, regulations issued by the Ministry of Corporate Affairs in this regard including any statutory amendments, modifications or re-enactment thereof and all other statutory approvals, as may be required and on recommendation of Nomination and Remuneration Committee and pursuant to approval of the Board of Directors (hereinafter referred to as "the Board"), the approval of the Members of the Company be and is hereby accorded for revision in remuneration and perquisites (hereinafter referred to as "remuneration") payable to Mr. Ketankumar Harkantbhai Joshi (DIN: 02089127), as Whole Time Director of the Company as set out in the explanatory statement attached hereto with effect from September 01, 2025, for his existing remaining term until revised further with other terms and conditions remaining unchanged

with the power to the Board of Directors to alter and modify the same, as per the provisions of the Act and in the best interest of the Company.

RESOLVED FURTHER THAT, subject to the provisions of Section 197 of the Companies Act, 2013 as amended from time and time, the Remuneration payable to Mr. Ketankumar Harkantbhai Joshi (DIN: 02089127) as set out in the explanatory statement attached hereto, in the event of loss or inadequacy of profit in any Financial Year, shall be as per the limit set out in Section II of Part II of Schedule V to the Companies Act, 2013.

RESOLVED FURTHER THAT for the purpose of giving effect to this Resolution, the Board of Directors (or any Committee thereof) be and is hereby authorized to undertake all acts, deeds and execute all documents and pass relevant resolutions for the purpose of giving effect to this resolution, including modification and amendment of any revisions, thereof and to enter into relevant agreement with the Director, as required, from time to time and to undertake all such steps, as may be deemed necessary in this matter.

RESOLVED FURTHER THAT the Board of Directors and/or the Company Secretary of the Company, either jointly or severally be and are hereby authorized to file the said resolution with the Registrar of Companies, and to do all such acts, deeds and things as may be necessary, expedient and incidental thereto to give effect to the above resolution."

For and on behalf of Board of Directors
Aristo Bio-Tech and Lifescience Limited
CIN: L01100GJ2005PLC127397

Registered office:
E-24/25/26, G.I.D.C., Ta. Savli,
Manjusar, Vadodara-391775,Gujarat

Place: Vadodara
Date: August 22, 2025

Narendra Singh Barhat
Chairman and Managing Director
DIN: 00310306

Ketankumar Harkantbhai Joshi
Whole Time Director & CFO
DIN: 02089127

IMPORTANT NOTES

1. The Government of India, Ministry of Corporate Affairs has allowed conducting Annual General Meeting through Video Conferencing (VC) or Other Audio Visual Means (OAVM) and dispended the personal presence of the members at the meeting. Accordingly, the Ministry of Corporate Affairs issued Circular No. 14/2020 dated April 08, 2020, Circular No. 17/2020 dated April 13, 2020 and Circular No. 20/2020 dated May 05, 2020 and Circular No. 02/2021 dated January 13, 2021 and Circular No. 21/2021 dated December 14, 2021 and 02/2022 dated May 05, 2022, 10/2022 dated December 28, 2022 and 09/2023 dated September 25, 2023 and latest being 09/2024 dated September 19, 2024 ("MCA Circulars") and Circular no. SEBI/HO/CFD/ CMD1/CIR/P/2020/79 dated May 12, 2020, Circular No. SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated January 15, 2021, Circular No. SEBI/HO/CFD/ CMD2/CIR/P/2022/62 dated May 13, 2022, SEBI/ HO/CRD/PoD-2/P/CIR/2023/4 dated January 05, 2023 and Circular No. SEBI/HO/CFD/CFD-PoD-2/P/ CIR/2023/167 dated October 07, 2023 and Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated October 03, 2024 issued by the Securities Exchange Board of India ("SEBI Circular") prescribing the procedures and manner of conducting the Annual General Meeting through VC/OVAM. In terms of the said circulars, the 20th Annual General Meeting ("AGM") of the Members will be held through VC/ OAVM. Hence, Members can attend and participate in the AGM through VC/OAVM only. The detailed procedure for participation in the meeting through VC/OAVM is as per note no. 16 and available at the Company's website: https://www.aristobiotech.com/.

2. Information regarding appointment/re-appointment of Directors and Explanatory Statement in respect of special business to be transacted pursuant to Section 102 of the Companies Act, 2013 and/or Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is annexed hereto.

3. In view of the 'Green Initiatives in Corporate Governance' introduced by MCA and in terms of the provisions of the Act, members who are holding shares of the Company in physical mode, are required to register their email addresses, so as to enable the Company to send all notices/ reports/ documents/ intimations and other correspondences, etc., through emails in the electronic mode instead of receiving physical copies of the same. Members holding shares in dematerialised form, who have not registered their email addresses with Depository Participant(s), are requested to register/update their email addresses with their Depository Participant(s).

4. Pursuant to the Circular No. 14/2020 dated April 08, 2020, issued by the Ministry of Corporate Affairs, the facility to appoint proxy to attend and cast vote for the Members is not available for this AGM. However, the Body Corporates are entitled to appoint authorised representatives to attend the AGM through VC/OAVM and participate there at and cast their votes through e-voting.

5. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Act.

6. In accordance with the Secretarial Standard-2 on General Meetings issued by the Institute of Company Secretaries of India ("ICSI"), as revised with effect from April 01, 2024, read with Clarification/Guidance on applicability of Secretarial Standards 2 dated April 15, 2020 issued by the ICSI, the proceedings of the AGM shall be deemed to be conducted at the Registered Office of the Company which shall be the deemed venue of the AGM.

7. Pursuant to the provisions of Section 113 of the Act, Body Corporates/Institutional/Corporate members intending for their authorized representatives to attend the meeting are requested to send to the Company, on cs@aristobiotech.com with a copy marked to scsandcollp@gmail.com and evoting@nsdl.com from their registered Email ID a scanned copy (PDF/ JPG format) of certified copy of the Board Resolution/ Authority Letter authorizing their representative to attend and vote on their behalf at the meeting.

8. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not

include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.

9. In line with the Ministry of Corporate Affairs Circulars, the Notice calling the AGM has been uploaded on the website of the Company at https://www.aristobiotech.com/investors. The Notice can also be accessed from the websites of the Stock Exchange i.e. National Stock Exchange of India Limited at www.nseindia.com and the AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. www.evoting.nsdl.com .

10. The name of the RTA changed from "Link Intime India Private Limited" to "MUFG Intime India Private Limited" with effect from December 31, 2024, upon acquisition of Link group by Mitsubishi UFJ Trust & Banking Corporation. For more information about the RTA, please visit their website at www.in.mpms.mufg.com.

11. Since the AGM will be held through VC/ OAVM, the route map of the venue of the Meeting is not annexed hereto;

12. Members seeking any information with regard to accounts are requested to write to the Company at least 10 days before the meeting so as to enable the management to keep the information ready.

13. The Register of Directors' and Key Managerial Personnel and their shareholding maintained under Section 170 of the Act, the Register of contracts or arrangements in which the Directors are interested under Section 189 of the Act and all other documents referred to in the Notice will be available for inspection in electronic mode.

14. Pursuant to regulation 44(6) of the SEBI Listing Regulations, as amended, the Company is providing VC / OAVM facility to its members to attend the AGM.

15. **Process and manner for Members opting for voting through Electronic means:**

    i. Pursuant to the provisions of Section 108 of the Act read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI Listing Regulations (as amended), and the MCA Circulars, the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited ("NSDL"), as the Authorised e-Voting agency for facilitating voting through electronic means, as the authorised e-Voting agency. The facility of casting votes by Members using remote e-voting as well as e-voting system on the date of the AGM will be provided by NSDL.

    ii. Members whose names are recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the Cut-off date i.e. Monday, September 01, 2025, shall be entitled to avail the facility of remote e-voting as well as e-voting system on the date of the AGM. Any recipient of the Notice, who has no voting rights as on the Cut-off date, shall treat this Notice as intimation only.

    iii. A person who has acquired the shares and has become a Member of the Company after the dispatch of the Notice of the AGM and prior to the Cut-off date i.e. Monday, September 01, 2025, shall be entitled to exercise his/her vote either electronically i.e. remote e-voting or e-voting system on the date of the AGM by following the procedure mentioned in this part.

    iv. The remote e-voting will commence on Friday, September 5, 2025 at 9.00 a.m. and will end on Sunday, September 7, 2025 at 5.00 p.m. During this period, the Members of the Company holding shares either in physical mode or in demat mode as on the Cut-off date i.e. Monday, September 01, 2025 may cast their vote electronically. The Members will not be able to cast their vote electronically beyond the date and time mentioned above and the remote e-voting module shall be disabled for voting by NSDL thereafter.

    v. Once the vote on a resolution is casted by the Member, he/she shall not be allowed to change it subsequently or cast the vote again.

vi. The voting rights of the Members shall be in proportion to their share in the paid-up equity share capital of the Company as on the Cut-off date i.e. Monday, September 01, 2025.

vii. The Company has appointed M/s SCS and Co LLP, Practising Company Secretaries (Membership No. ACS: 41942; CP No: 23630), to act as the Scrutiniser for remote e-voting as well as the e-voting on the date of the AGM, in a fair and transparent manner.

viii. SEBI vide Circular Nos. SEBI/HO/OIAE/OIAE_IAD-1/P/ CIR/2023/131 dated July 31, 2023, and SEBI/HO/OIAE/ OIAE_IAD-1/P/CIR/2023/135 dated August 4, 2023, read with Master Circular No. SEBI/HO/ OIAE/OIAE_IAD-1/P/ CIR/2023/145 dated July 31, 2023 (updated as on August 11, 2023), has established a common Online Dispute Resolution Portal ("ODR Portal") for resolution of disputes arising in the Indian Securities Market. Pursuant to above-mentioned circulars, post exhausting the option to resolve their grievances with the RTA/ Company directly and through existing SCORES platform, the investors can initiate dispute resolution through the ODR Portal (https://smartodr.in/login).

16. **The procedure and instructions for remote e-voting are, as follows:**

The remote e-voting period begins on Friday, September 5, 2025 at 9.00 A.M. (IST) and will end on Sunday, September 7, 2025 at 5.00 P.M. (IST). The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. on Monday, September 01, 2025 may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being Monday, September 01, 2025.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access To NSDL E-Voting System:

a) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode:

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

TYPE OF SHAREHOLDERS	LOGIN METHOD
Individual Shareholders holding securities in demat mode with NSDL.	1. For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID,8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2. Existing IDeAS user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "Beneficial Owner"

	icon under "Login" which is available under 'IDeAS' section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 3. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS Portal" or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 4. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen-digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 5. Shareholders/Members can also download NSDL Mobile App "NSDL Speede" facility by scanning the QR code mentioned below for seamless voting experience. 
Individual Shareholders holding securities in demat mode with CDSL	1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password. 2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

	Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 4. Alternatively, the user can directly access e-Voting page by providing demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at above mentioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

LOGIN TYPE	HELPDESK DETAILS
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at toll free no.: 1800 1020 990 and 1800 22 44 30
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022- 23058738 or 022-23058542-43

B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.
   Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.

4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example, if your DP ID is IN300*** and Client ID is 12****** then your user ID is IN300***12******.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example, if your Beneficiary ID is 12********** then your user ID is 12**********
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example, if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:
   a) If you are already registered for e-Voting, then you can user your existing password to login and cast your vote.
   b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
   c) How to retrieve your 'initial password'?
      (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8-digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
      (ii) If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered

6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
   a) Click on "Forgot User Details/Password?"(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
   b) Physical User Reset Password?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
   c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
   d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.

7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.

8. Now, you will have to click on "Login" button.

9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast Your Vote Electronically and Join General Meeting on NSDL E-Voting System.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1) After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and who's voting cycle and General Meeting is in active status.
2) Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join Meeting".
3) Now you are ready for e-Voting as the Voting page opens.
4) Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
5) Upon confirmation, the message "Vote cast successfully" will be displayed.
6) You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7) Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders:

1) Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to scsandcollp@gmail.com with a copy marked to evoting@nsdl.com. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.

2) It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.

3) In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: 1800 1020 990 and 1800 22 44 30 or send a request to at evoting@nsdl.com

Process for those shareholders whose Email Ids are not registered with the depositories for procuring User Id and Password and registration of E-Mail Ids for E-Voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to cs@aristobiotech.com .

2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) to cs@aristobiotech.com .

3. If you are an Individual shareholder holding securities in demat mode, you are requested to refer to the login method explained at step 1 (A) i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.

4. Alternatively, shareholder/members may send a request to evoting@nsdl.com for procuring user id and password for e- voting by providing above mentioned documents.

5. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

The instructions for members for e-voting on the day of the 20th AGM are as under:

1. The procedure for e-Voting on the day of the 20th AGM is same as the instructions mentioned above for remote e- voting.

2. Only those Members/ shareholders, who will be present in the 20th AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.

3. Members who have voted through Remote e-Voting will be eligible to attend the 20th AGM. However, they will not be eligible to vote at the AGM.

4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

Instructions for members for attending the 20th AGM through VC/OAVM are as under:

1. Members will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for Access to NSDL e-Voting system. After successful login, you can see link of "VC/OAVM link" placed under "Join General meeting" menu against company name. You are requested to click on VC/OAVM link placed under Join General Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.

2. Members are encouraged to join the Meeting through Laptops for better experience.

3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.

4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.

5. Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at cs@aristobiotech.com. The same will be replied by the company suitably.

6. For ease of conduct, Members who would like to ask questions may send their questions in advance at least seven (7) days before AGM mentioning their name, demat account number/folio number, email id, mobile number at cs@aristobiotech.com and register themselves as a speaker. Those Members who have registered themselves as a speaker will only be allowed to express their views/ask questions during the AGM.

7. Since the AGM will be held through VC/OAVM, the Route Map is not annexed in this Notice.

17. The Scrutinizer shall, after the conclusion of voting at the AGM, unblock the votes cast through remote e-Voting and count the same, and count the votes cast during the AGM, and shall make, not later than Two working days from the conclusion of the AGM, a consolidated Scrutinizer's Report of the total votes cast in favour or against, if any, to the Chairman or a person authorised by him in writing, who shall countersign the same and declare the result of the voting forthwith. The Scrutinizer's decision on the validity of the votes shall be final.

    The results declared along with the Scrutinizer's Report shall be placed on the Company's website www.aristobiotech.com and on the website of NSDL www.evoting.nsdl.com within two working days of the passing of the Resolutions at the 20th Annual General Meeting of the Company and shall also be communicated to the Stock Exchanges where the shares of the Company are listed.

Information on dividend:

1. Members may note that the Board of Directors at its meeting held on May 29, 2025, has recommended a final dividend of INR 0.50/- per equity share for the financial year ended March 31, 2025. The final dividend, if approved at the AGM, will be paid on or before October 07,2025 to those Members whose names are on the Company's Register of Members and to those whose names appear as Beneficial Owners as at the close of the business hours on Friday, September 01, 2025 as per the details to be furnished by the Depositories, viz. NSDL and CDSL for this purpose.
2. Dividends, if not encashed for a period of 7 years from the date of transfer to Unpaid Dividend Accounts of the Company, are liable to be transferred to the Investor Education and Protection Fund ("IEPF"). Further, the shares in respect of which dividend has remained unclaimed for 7 consecutive years or more from the date of transfer to unpaid dividend accounts shall also be transferred to IEPF. In view of this, Members are requested to claim their dividends from the Company, within the stipulated timeline.
3. In accordance with the provisions of the Income Tax Act, 1961 as amended by and read with the provisions of the Finance Act, 2020, with effect from April 1, 2020, dividend declared and paid by the Company is taxable in the hands of its Members and the Company is required to deduct tax at source (TDS) from dividend paid to the Members at the applicable rates.
4. In general, to enable compliance with TDS requirements, Members are requested to complete and/or update their Residential Status, valid PAN linked to Aadhaar and Category as per the IT Act with their Depository Participants ("DPs") or in case shares are held in physical form, with the Company.
5. A Resident individual shareholder with PAN and who is not liable to pay income tax can submit a yearly declaration in Form No. 15G / 15H, to avail the benefit of non-deduction of tax at source by e-mail to cs@aristobiotech.com by August 28, 2025. Shareholders are requested to note that in case their PAN is not registered, the tax will be deducted at a higher rate of 20%.

    Non-resident shareholders [including Foreign Institutional Investors (FIIs) / Foreign Portfolio Investors (FPIs)] can avail beneficial rates under tax treaty between India and their country of tax residence, subject to providing necessary documents i.e. No Permanent Establishment and Beneficial Ownership Declaration, Tax Residency Certificate, Form 10F, any other document which may be required to avail the tax treaty benefits. For this purpose the shareholder may submit the above documents (PDF / JPG Format) by e-mail to mail@aristobiotech.com. The aforesaid declarations and documents need to be submitted by the shareholders August 28, 2025.
6. Members holding shares in electronic form are hereby informed that bank particulars registered with their respective depository participants empanelled with NSDL / CDSL, will be used by the Company for payment of dividend. To avoid the delay in receiving the dividend, Members are requested to update their KYC details with their DPs.

Contact details:

COMPANY	**Address**: E/26, G.I.D.C., Manjusar Ta. Savli, Vadodara -391775, Gujarat. **Tel No**. +91-2667-264843/41 **Email:** mail@aristobiotech.com **Web:** www.aristobiotech.com
REGISTRAR AND TRANSFER AGENT	MUFG Intime India Private Limited (Previously known as LINK Intime Private Limited) **CIN:** U67190MH1999PTC118368 **Address** – C -101, 247 Park, L B S Marg, Vikhroli West, Mumbai 400083; **Tel no.** – 022 - 4918 6000 **E-mail** – mumbai@in.mpms.mufg.com
E-VOTING AGENCY & VC / OAVM	**E-mail**: evoting@nsdl.com NSDL help desk 1800-222-990
SCRUTINIZER	M/s SCS and Co LLP, Ms. Anjali Sangtani (Membership No. A41942 C P No.: 23630) Partner Email: scsandcollp@gmail.com. ; Mo No: +91 8128156833

EXPLANATORY STATEMENT

(Pursuant to Section 102 (1) of the Companies Act 2013 and Secretarial Standard 2 on General Meetings)

ITEM NO: 4

TO RE-APPOINT M/S PRAKASH CHANDRA JAIN & CO., CHARTERED ACCOUNTANTS (FRN: 002438C) AS STATUTORY AUDITORS OF THE COMPANY FOR SECOND TERM OF FOUR YEARS: ORDINARY RESOLUTION

M/s. Prakash Chandra Jain & Co., Chartered Accountants (FRN: 002438C), were appointed as Statutory Auditors of the Company at the AGM held on December 31, 2020 to hold office from the conclusion of the said meeting till the conclusion of the 20th AGM to be held in the year 2025. In terms of the provisions of Section 139 of the Companies Act, 2013, the Companies (Audit and Auditors) Rules, 2014, and other applicable provisions, the Company can appoint or reappoint an audit firm as Statutory Auditors for not more than two (2) terms of five (5) consecutive years. M/s. Prakash Chandra Jain & Co is eligible for reappointment for a further period of four years. Based on the recommendation of the Audit Committee, the Board of Directors, at its meeting held on August 14, 2025, approved the reappointment of M/s. Prakash Chandra Jain & Co as the statutory auditors of the Company to hold office for a second term of four consecutive years from the conclusion of the ensuing AGM until the conclusion of the AGM to be held in the year 2029. The reappointment is subject to approval of the shareholders of the Company.

The Board of Directors, in consultation with the Audit Committee, may alter and vary the terms and conditions of appointment, including remuneration, in such manner and to such extent as may be mutually agreed with the statutory auditors.

Considering the evaluation of the past performance, experience and expertise of M/s. Prakash Chandra Jain & Co and based on the recommendation of the Audit Committee, it is proposed to appoint M/s. Prakash Chandra Jain & Co as Statutory Auditors of the Company for a second term of four consecutive years till the conclusion of the 24th AGM of the Company in terms of the aforesaid provisions.

Brief Profile of Prakash Chandra Jain & Co:

M/s. Prakash Chandra Jain & Co. was incorporated in 1981, since then it has grown in size and established its branch office in Baroda and Mumbai. The firm has continuously improved upon its infrastructure development to see that it will be able to render faster and more effective services to the client. As a mark of its good working practices, the firm is regularly getting substantial Audits from the Comptroller and Auditor General of India (CAG). The head office of the firm is situated at 101, Building 3D, Dheeraj Enclave CHSL, Opp. Bhor Industries, W.E. Highway,Borivali (E), Mumbai – 400 066.

None of the Directors and Key Managerial Personnel of the Company and their respective relatives are concerned or interested, financially or otherwise, in passing the proposed Resolution.

The Board recommends the resolution set forth in item no. 4 for the approval of Members.

ITEM NO. 5:

TO RATIFY THE REMUNERATION PAYABLE TO THE COST AUDITORS FOR THE FINANCIAL YEAR 2025- 2026: ORDINARY RESOLUTION

Members may note that as per Section 148 of the Act read with the Companies (Cost Records and Audit) Rules, 2014, your Company is required to maintain cost records and appoint a Cost Auditor to have the cost records audited on annual basis.

The Board of Directors, based on the recommendation of the Audit Committee, at their meeting held on August 14, 2025, had approved the re-appointment of M/s. YS Thakar & Co, Cost Accountants (Firm Registration No.: 000318) as Cost Auditors to carry out cost audit for the financial year 2025-2026.

In accordance with Section 148(3) the Act read with Rule 14 of the Companies (Audit and Auditors) Rules, 2014, the remuneration so payable to the Cost Auditors is required to be ratified by the Members of the Company.

In making the decision on the appointment and remuneration of the Cost Auditors, the Audit Committee considered the Cost Auditors' performance during the previous year(s) in examining and verifying the accuracy of the cost accounting records maintained by the Company.

The Cost Auditors have furnished a certificate regarding their eligibility for appointment as Cost Auditors of the Company. They have vast experience in the field of cost audit and have conducted the audit of the cost records of the Company for previous years under the provisions of the Act.

The Board of Directors accordingly recommend the passing of the said resolution as contained in the Notice for approval by the Members as an ordinary resolution.

Based on the recommendation of the Audit Committee, the Board of Directors propose a remuneration of INR 64,900/- (Rupees Sixty Four Thousand Nine Hundred Only) excluding out of pocket expenses & taxes, as applicable, payable to M/s. YS Thakar & Co, Cost Accountants., Cost Accountants for conducting Cost Audit for FY 2025-2026.

None of the Directors and/or Key Managerial Personnel of the Company and/or their relatives are concerned or interested in the Resolution set out in Item No. 5 of this Notice, except to the extent of their shareholding in the Company.

ITEM NO.6 TO APPROVE REVISION IN REMUNERATION PAYABLE TO MR. NARENDRA SINGH BARHAT (DIN: 00310306), CHAIRMAN AND MANAGING DIRECTOR OF THE COMPANY: SPECIAL RESOLUTION

Mr. Narendra Singh Barhat (DIN: 00310306**)** is acting as Director of the Company since March 17, 2005. Later on, the Board of Directors of the Company, in their Meeting held on September 10, 2018, had appointed Mr. Narendra Singh Barhat, as Managing Director for the period of 5 years w.e.f. September 10, 2018. The terms and conditions of appointment and remuneration of Mr. Narendra Singh Barhat(DIN: 00310306**)** as Managing Director of the Company was also approved by the Members of the Company in their General Meeting held on September 29, 2018. Further, he was re-appointed by the members of the Company in their meeting held on September 26, 2023 for a further period of 5 years w.e.f. September 10, 2023.

On the recommendation of the Nomination and Remuneration Committee of the Company and looking to the contributions made by Mr. Narendra Singh Barhat(DIN: 00310306) which helped the Company to grow at faster rate than past, the Board, in its meeting held on August 22, 2025, has considered approval of limit of remuneration, i.e. up to ₹ 75.00 Lakhs per annum w.e.f. September 01, 2025 with such increments as may be decided by the Board from time to time to be paid to Mr. Narendra Singh Barhat, for his remaining tenure as Chairman & Managing Director. The other terms and conditions of his appointment shall remain unchanged.

The Nomination and Remuneration Committee has also noted that the Company has not made any default in repayment of its dues to Banks or Financial Institutions.

Further, as per the provisions of Section 197 the Companies Act, 2013 as amended from time and time, the minimum Remuneration payable to Mr. Narendra Singh Barhat (DIN: 00310306), in the event of loss or inadequacy of profit in any Financial Year, shall be as per the limit set out in Section II of Part II of Scheduled V to the Companies Act, 2013 or any other applicable limits, as provided by the Central Government in this regard, from time to time.

Pursuant to Sections 196, 197, 198, 203 and all other applicable provisions of the Act and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force), the remuneration payable to Mr. Narendra Singh Barhat (DIN: 00310306) is now being placed before the Members for their approval by way of Special Resolution.

The relevant disclosures in terms of Schedule V to the Companies Act, 2013 is given hereunder;

GENERAL INFORMATION:

Nature of Industry:

Our Company is an agrochemical company engaged in the manufacturing, formulation, supplying, packaging and job work services in various Pesticides such as Insecticides, Herbicides, Fungicides, Plant Growth Regulators and a wide variety of other Agrochemicals for India as well as for Export.

Date of commencement of commercial production:

The Commercial Production has been commenced since incorporation of the Company.

In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus:

Not Applicable

Financial performance based on given indicators:

(Rs. In Lakhs)

PARTICULARS	F.Y. 2024-25	F.Y. 2023-24
Revenue From Operations	31,809.27	24,514.79
Other Income	45.36	18.04
Total Income	**31,854.63**	**24,532.83**
Less: Total Expenses Before Depreciation, Finance Cost and Tax	30,881.92	23,665.59
Profit Before Depreciation, Finance Cost and Tax	972.71	867.24
Less: Depreciation	260.24	157.07
Less: Finance Cost	165.77	169.41
Profit Before Tax	**546.69**	**540.76**
Less: Short Provision of Taxes in Earlier Year	-	0.31
Less: Current Tax	144.07	138.69
Less: Deferred Tax Liability (Liability)	(3.69)	12.19
Profit After Tax	**406.31**	**389.57**
Earning Per Share (Basic & Diluted)	5.97	5.72

Export performance and net foreign exchange:

During the year under review, the company have Rs. 489.53 Lakhs export performance and Rs. 2130.49 Lakhs net foreign exchange expenditure.

Foreign Investment and collaborations, if any:

No collaborations have been made by the Company with any of foreign entity. Further, as at March 31, 2025 total holding of Foreign Shareholders was 38,400 Equity Shares.

Information about the Director:

Background Details:

Mr. Barhat, aged 69 years, has been serving as the chairman and Executive Director and also the Promoter of our Company since March 17, 2005. With a fresh perspective and dynamic approach, he contributes to the company's

strategic growth and operational efficiency. His leadership and vision play a key role in driving innovation and expanding the company's market presence.

Past Remuneration:

In the financial year 2024-25, Mr. Narendra Singh Barhat was paid total remuneration and perquisite of ₹ 48.00 Lakh as Chairman & Managing Director.

Recognition or awards:

Nil

Job Profile and his suitability:

As the chairman and Managing Director of the Company, he contributes to the company's strategic growth and operational efficiency. His leadership and vision play a key role in driving innovation and expanding the company's market presence, he is a fit and proper person as the Managing Director of the Company.

Revised Terms and conditions of Remuneration: -

1. Basic Salary up to ₹ 75,00,000/- per annum for the existing remaining term w.e.f. September 01, 2025;
2. Mr. Narendra Singh Barhat (DIN: 00310306) will be paid perquisites and allowances like HRA, medical reimbursement, travelling allowances, club fees and other payments in the nature of perquisites and allowances as agreed by the Board of Directors, subject to overall ceiling of remuneration stipulated in sections 2(78) and 197 read with Schedule V to the Act.

Comparative Remuneration profile with respect to industry, size of the Company, profile of the position and person:

Taking into consideration the size of the Company, the profile of Mr. Narendra Singh Barhat, the responsibilities shouldered by him and the industry benchmarks, the remuneration proposed to be paid is commensurate with the remuneration packages paid to similar senior level incumbents, in other companies.

Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any:

Mr. Narendra Singh Barhat has pecuniary relationship to the extent he is Promoter – Chairman & Managing Director - Shareholder of the Company. He is also husband of Mrs. Kusum Narendra Singh Barhat, Executive Director of the Company.

In compliance with the provisions of Sections 196, 197, 198 and other applicable provisions of the Act, read with Schedule V to the Act, the terms of revised remuneration specified above are now being submitted to the Members for their approval. Further, remuneration proposed above shall be valid for the existing remaining term of Mr. Narendra Singh Barhat (DIN 00310306) until revised further with other terms and conditions remaining unchanged as per the resolution passed.

The Board of Directors is of the view that the revision in Remuneration payable to Mr. Narendra Singh Barhat (DIN 00310306) for the existing remaining term as Chairman & Managing Director will be beneficial to the operations of the Company and the same is commensurate with his abilities and experience and accordingly recommends the Special Resolution at Item No. 6 of the accompanying Notice for approval by the Members of the Company.

Except Mr. Narendra Singh Barhat himself and Mrs. Kusum Narendra Singh Barhat and their relatives to the extent of their shareholding in the Company, none of the Directors or Key Managerial Personnel of the Company including their relatives is interested or concerned in the Resolution.

The statement of additional information required to be disclosed as per Regulation 36(3) of SEBI (LODR) Regulations, 2015 and Secretarial Standard II issued by ICSI is attached at the end of this Explanatory Statement and must be read as the part of this Notice.

ITEM NO. 07 TO APPROVE REVISION IN REMUNERATION PAYABLE TO MRS. KUSUM NARENDRA SINGH BARHAT(DIN: 00310065) EXECUTIVE DIRECTOR OF THE COMPANY: SPECIAL RESOLUTION

Mrs. Kusum Narendra Singh Barhat (DIN 00310065) has been acting as in Executive Director of the Company since March 17, 2005. Looking to the contributions made by Mrs. Kusum Narendra Singh Barhat (DIN 00310065) which helped the Company to grow at faster rate than past, and on the recommendation of the Nomination and Remuneration Committee of the Company, the Board, in its meeting held on August 22, 2025 has considered the revision in salary and perquisites (hereinafter referred to as "remuneration") payable to Mrs. Kusum Narendra Singh Barhat (DIN 00310065) Executive Director of the Company with effect from September 01, 2025, subject to the approval of the Shareholders at this Annual General Meeting.

The Nomination and Remuneration Committee has also noted that the Company has not made any default in repayment of its dues to Banks or Financial Institutions.

Further, in terms of SEBI LODR Regulations the remuneration of the Promoter Executive Directors shall not exceed Rs. 5,00,00,000 (Rupees Five crore) or 2.5% of net profits whichever is higher or there is more than one Executive Directors, the aggregate annual remuneration to such directors is exceeds 5%of the net profit. The prescribed resolution required approval of Shareholders of the company as special resolution under these regulations.

Further, as per the provisions of Section 197 the Companies Act, 2013 as amended from time and time, the minimum Remuneration payable to Mrs. Kusum Narendra Singh Barhat (DIN 00310065) in the event of loss or inadequacy of profit in any Financial Year, shall be as per the limit set out in be Section II of Part II of Scheduled V to the Companies Act, 2013 or any other applicable limits, as provided by the Central Government in this regard, from time to time.

Pursuant to Sections 196, 197, 198 and all other applicable provisions of the Act and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force), the remuneration payable to Mrs. Kusum Narendra Singh Barhat (DIN 00310065) is now being placed before the Members for their approval by way of Special Resolution.

The relevant disclosures in terms of Schedule V to the Companies Act, 2013 is given hereunder;

GENERAL INFORMATION:

Nature of Industry:

Our Company is an agrochemical company engaged in the manufacturing, formulation, supplying, packaging and job work services in various Pesticides such as Insecticides, Herbicides, Fungicides, Plant Growth Regulators and a wide variety of other Agrochemicals for India as well as for Export.

Date of commencement of commercial production:

The Commercial Production has been commenced since incorporation of the Company.

In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus:

Not Applicable

Financial performance based on given indicators:

(Rs. In Lakhs)

PARTICULARS	F.Y. 2024-25	F.Y. 2023-24
Revenue From Operations	31,809.27	24,514.79
Other Income	45.36	18.04
Total Income	**31,854.63**	**24,532.83**
Less: Total Expenses Before Depreciation, Finance Cost and Tax	30,881.92	23,665.59
Profit Before Depreciation, Finance Cost and Tax	972.71	867.24
Less: Depreciation	260.24	157.07
Less: Finance Cost	165.77	169.41
Profit Before Tax	**546.69**	**540.76**
Less: Short Provision of Taxes in Earlier Year	-	0.31
Less: Current Tax	144.07	138.69
Less: Deferred Tax Liability (Liability)	(3.69)	12.19
Profit After Tax	**406.31**	**389.57**
Earning Per Share (Basic & Diluted)	5.97	5.72

Export performance and net foreign exchange:

During the year under review, the company have Rs. 489.53 Lakhs export performance and Rs. 2130.49 Lakhs net foreign exchange expenditure.

Foreign Investment and collaborations, if any:

No collaborations have been made by the Company with any of foreign entity. Further, as at March 31, 2025 total holding of Foreign Shareholders was 38,400 Equity Shares.

INFORMATION ABOUT THE DIRECTOR:

Background Details:

Mrs. Kusum, aged 63 years, has been serving as the Executive Director and also the Promoter of our Company since March 17, 2005. With a fresh perspective and dynamic approach, she contributes to the company's strategic growth and operational efficiency. Her leadership and vision play a key role in driving innovation and expanding the company's market presence.

Past Remuneration:

In the financial year 2024-25, Mrs. Kusum Narendra Singh Barhat (DIN 00310065) was paid total remuneration and perquisite of ₹ 27.00 Lakh as Executive Director.

Recognition or awards:

Nil

Job Profile and her suitability:

She is looking after overall Matriculate of the Company. She develops corporate plans for a variety of HR matters such as compensation, benefits, health and safety. She manages programs and lead staff while also possess a strong strategic mindset and she is a fit and proper person as the Executive Director of the Company.

Revised Terms and conditions of Remuneration: -

1. Basic Salary up to ₹ 5,00,000/- per month for the existing remaining term w.e.f. September 01, 2025;

Comparative Remuneration profile with respect to industry, size of the Company, profile of the position and person:

Taking into consideration the size of the Company, the profile of Mrs. Kusum Narendra Singh Barhat, the responsibilities shouldered by her and the industry benchmarks, the remuneration proposed to be paid is commensurate with the remuneration packages paid to similar senior level incumbents, in other companies.

Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any:

Mrs. Kusum Narendra Singh Barhat (DIN: 00310065) has pecuniary relationship to the extent she is Promoter – Director - Shareholder of the Company.

She is also wife of Mr. Narendra Singh Barhat (DIN: 00310306), chairman & Managing Director of the Company.

In compliance with the provisions of Sections 197, 198 and other applicable provisions of the Act, read with Schedule V to the Act, the appointment of Mrs. Kusum Narendra Singh Barhat (DIN:00310065), as an Executive Director of the Company is now being placed before the Members for their approval. Further, remuneration proposed above shall be valid for the existing term of Mrs. Kusum Narendra Singh Barhat (DIN:00310065) until revised further with other terms and conditions remaining unchanged as per the resolution passed.

Mrs. Kusum Narendra Singh Barhat (DIN:00310065) for the term as Executive Director will be beneficial to the operations of the Company and the same is commensurate with her abilities and experience and accordingly recommends the Special Resolution at Item No. 07 of the accompanying Notice for approval by the Members of the Company.

Except Mrs. Kusum Narendra Singh Barhat herself and Mr. Narendra Singh Barhat and their relatives to the extent of their shareholding in the Company, none of the Directors or Key Managerial Personnel of the Company including their relatives is interested or concerned in the Resolution.

In compliance with the provisions of Sections 197, 198 and other applicable provisions of the Act, read with Schedule V to the Act, the ratification of remuneration specified above for the remaining tenure as an Executive Director to Mrs. Kusum Narendra Singh Barhat, is now being placed before the Members for their approval. The Board of Directors recommends the Special Resolution at Item No.7 of the accompanying Notice for approval by the Members of the Company.

The statement of additional information required to be disclosed as per Regulation 36(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and Secretarial Standard II issued by ICSI is attached at the end of this Explanatory Statement and must be read as the part of this Notice.

ITEM NO. 08 TO APPROVE REVISION IN REMUNERATION PAYABLE TO MR. KETANKUMAR HARKANTBHAI JOSHI (DIN: 02089127), WHOLE TIME DIRECTOR OF THE COMPANY: SPECIAL RESOLUTION

Mr. Ketankumar Harkantbhai Joshi (DIN: 02089127) was originally appointed on the Board on August 27, 2018 and further designated as the Whole Time Director of the Company on March 20, 2022 for a period of 5 years.

On the recommendation of the Nomination and Remuneration Committee of the Company, the Board, in its meeting held on August 22, 2025, has considered approval of limit of remuneration, i.e. upto Rs. 5.00 Lakh per annum with such increments as may be decided by the Board from time to time to be paid to Mr. Ketankumar Harkantbhai Joshi (DIN: 02089127) for his remaining tenure as Whole Time Director. The other terms and conditions of his appointment, shall remain unchanged.

The Nomination and Remuneration Committee has also noted that the Company has not made any default in repayment of its dues to Banks or Financial Institutions.

Further, as per the provisions of Section 197 the Companies Act, 2013 as amended from time and time, the minimum Remuneration payable to Mr. Ketankumar Harkantbhai Joshi (DIN: 02089127), in the event of loss or inadequacy of profit in any Financial Year, shall be as per the limit set out in be Section II of Part II of Scheduled V to the Companies Act, 2013 or any other applicable limits, as provided by the Central Government in this regard, from time to time.

Pursuant to Sections 196, 197, 198, 203 and all other applicable provisions of the Act and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force) and other applicable Regulations of SEBI (LODR) Regulations, 2015, remuneration payable to Mr. Ketankumar Harkantbhai Joshi (DIN: 02089127), as Whole Time Director is now being placed before the Members for their approval by way of Special Resolution.

The relevant disclosures in terms of Schedule V to the Companies Act, 2013 is given hereunder;

GENERAL INFORMATION:

Nature of Industry:

Our Company is an agrochemical company engaged in the manufacturing, formulation, supplying, packaging and job work services in various Pesticides such as Insecticides, Herbicides, Fungicides, Plant Growth Regulators and a wide variety of other Agrochemicals for India as well as for Export.

Date of commencement of commercial production:

The Commercial Production has been commenced since incorporation of the Company.

In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus:

Not Applicable

Financial performance based on given indicators:

(Rs. In Lakhs)

PARTICULARS	F.Y. 2024-25	F.Y. 2023-24
Revenue From Operations	31,809.27	24,514.79
Other Income	45.36	18.04
Total Income	**31,854.63**	**24,532.83**
Less: Total Expenses Before Depreciation, Finance Cost and Tax	30,881.92	23,665.59
Profit Before Depreciation, Finance Cost and Tax	972.71	867.24
Less: Depreciation	260.24	157.07
Less: Finance Cost	165.77	169.41
Profit Before Tax	**546.69**	**540.76**
Less: Short Provision of Taxes in Earlier Year	-	0.31
Less: Current Tax	144.07	138.69

PARTICULARS	F.Y. 2024-25	F.Y. 2023-24
Less: Deferred Tax Liability (Liability)	(3.69)	12.19
Profit After Tax	**406.31**	**389.57**
Earning Per Share (Basic & Diluted)	5.97	5.72

Export performance and net foreign exchange:

During the year under review, the company have Rs. 489.53 Lakhs export performance and Rs. 2130.49 Lakhs net foreign exchange expenditure.

Foreign Investment and collaborations, if any:

No collaborations have been made by the Company with any of foreign entity. Further, as at March 31, 2025 total holding of Foreign Shareholders was 38,400 Equity Shares.

Information about the Director:

Background Details:

Mr. Ketankumar Harkantbhai Joshi, aged 54 years is the Whole Time Director and also the Promoter of our Company. He holds degree in Bachelor in Mechanical Engineering. He is having experience of 28 years in agrochemical industry. He helped the organization to reach to new heights in its initial stage of incorporation with the help of his substantial experiences and knowledge gained throughout his journey. He has vast knowledge of the business & related industries.

Past Remuneration:

In the financial year 2024-25, Mr. Ketankumar Harkantbhai Joshi was paid total remuneration and perquisite of ₹ 27.00 Lakh as Whole-Time Director.

Recognition or awards:

Nil

Job Profile and his suitability:

As the Whole-time director of the Company, he contributes to the company's strategic growth and operational efficiency. His leadership and vision play a key role in driving innovation and expanding the company's market presence, he is a fit and proper person as the Managing Director of the Company.

Revised Terms and conditions of Remuneration: -

1. Basic Salary up to ₹ 5,00,000/- per month for the existing remaining term w.e.f. September 01, 2025;
2. Mr. Ketankumar Harkantbhai Joshi will be paid perquisites and allowances like HRA, medical reimbursement, travelling allowances, club fees and other payments in the nature of perquisites and allowances as agreed by the Board of Directors, subject to overall ceiling of remuneration stipulated in sections 2(78) and 197 read with Schedule V to the Act.

Comparative Remuneration profile with respect to industry, size of the Company, profile of the position and person:

Taking into consideration the size of the Company, the profile to Mr. Ketankumar Harkantbhai Joshi the responsibilities shouldered by him and the industry benchmarks, the remuneration proposed to be paid is commensurate with the remuneration packages paid to similar senior level incumbents, in other companies.

Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any:

Mr. Ketankumar Harkantbhai Joshi (DIN:02089127) has pecuniary relationship to the extent he is Promoter – Director - Shareholder of the Company.

In compliance with the provisions of Sections 196, 197, 198 and other applicable provisions of the Act, read with Schedule V to the Act, the appointment of Mr. Ketankumar Harkantbhai Joshi (DIN:02089127), as a Whole Time Director of the Company is now being placed before the Members for their approval. Further, remuneration proposed above shall be valid for the existing term of Mr. Ketankumar Harkantbhai Joshi until revised further with other terms and conditions remaining unchanged as per the resolution passed.

Mr. Ketankumar Harkantbhai Joshi for the term as Whole Time Director will be beneficial to the operations of the Company and the same is commensurate with his abilities and experience and accordingly recommends the Special Resolution at Item No. 08 of the accompanying Notice for approval by the Members of the Company.

Except Mr. Ketankumar Harkantbhai Joshi himself and his relatives to the extent of their shareholding in the Company, none of the Directors or Key Managerial Personnel of the Company including their relatives is interested or concerned in the Resolution.

The statement of additional information required to be disclosed as per Regulation 36(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and Secretarial Standard II issued by ICSI is attached at the end of this Explanatory Statement and must be read as the part of this Notice.

For and on behalf of Board of Directors
Aristo Bio-Tech and Lifescience Limited
CIN: L01100GJ2005PLC127397

Registered office:
E-24/25/26, G.I.D.C., Ta. Savli,
Manjusar, Vadodara-391775,Gujarat

Place: Vadodara
Date: August 22, 2025

Narendra Singh Barhat
Chairman and Managing Director
DIN: 00310306

Ketankumar Harkantbhai Joshi
Whole Time Director & CFO
DIN: 02089127

ANNEXURE TO THE NOTICE

DISCLOSURE UNDER REGULATION 36 (3) OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 AND SECRETARIAL STANDARDS-II ISSUED BY ICSI FOR ITEM NO. 2:

Details of Director Retiring by Rotation/ Seeking Appointment/ Re-Appointment at the ensuing Annual General Meeting

Name	Laxman Singh Rathore
Date of Birth	04/07/1954 (71 Years)
Qualification	Bachelor of Science
Experience - Expertise in specific functional areas - Job profile and suitability	He holds degree in Bachelor of Science having experience of 40 years in Meteorological Department and Weather Forecasting. His extensive experience and education in meteorology can drive innovation, improve decision-making, and enhance risk management within your company, ultimately contributing to growth and success.
No. of Shares held as on March 31, 2025 including shareholding as a Beneficial Owner.	--
Terms & Conditions	Liable to retire by rotation
Remuneration Last Drawn	NIL
Remuneration sought to be paid	NIL
Number of Board Meetings attended during the Financial Year 2024-25	8 Meeting out of 8 Board Meetings
Date of Original Appointment	20/03/2022
Date of Appointment in current terms	20/03/2022
Directorships held in public companies including deemed public companies	Nil
Memberships/Chairmanships of committees of public companies*	Chairmanship: Nil Membership: 2
Inter-se Relationship with other Directors.	NIL
Information as required pursuant to NSE Circular No. L1ST/COMP/14/2018- 19 dated June 20, 2018	Mr. Laxman Singh Rathore is not debarred from holding the office of director pursuant to any SEBI order.

**Includes only Audit Committee and Stakeholders' Relationship Committee.*

ANNEXURE TO THE NOTICE

DISCLOSURE UNDER REGULATION 36 (3) OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 AND SECRETARIAL STANDARDS-II ISSUED BY ICSI FOR ITEM NO. 6,7,8:

Details of Director Retiring by Rotation/ Seeking Appointment/ Re-Appointment/Revision in Remuneration at the ensuing Annual General Meeting

Name of Director	Mr. Narendra Singh Barhat	Mrs. Kusum Narendra Singh Barhat	Mr. Ketankumar Harkantbhai Joshi
Date of Birth	08/09/1955	02/03/1962	25/12/1970
Educational Qualifications	Bachelor of science-Agriculture	Under Matriculate	Bachelor in Mechanical Engineering
Expertise in specific functional areas - Job profile and suitability	He has over 47 years of experience in the chemical pesticides, fertilizers, insecticides, and weedicides industry. He oversees operations with a focus on micromanagement, task delegation, and consistent performance. Known for his adaptability, he swiftly responds to industry changes and leads innovation through new product development. His strong research skills, combined with a persuasive, logical, and inspiring leadership style, make him a valuable asset to the company.	She has over 30 years of experience in administration and management, contributing significantly to the company's growth and success. She develops strategic corporate plans across HR functions, including compensation, benefits, and health and safety. With a strong leadership presence, she manages programs, leads teams, and serves as a vital link between top management, employees, and labor unions. Her deep knowledge, dedication, and commitment to compliance with internal policies and legal standards have been instrumental in taking the company to new heights.	He is having experience of 28 years in agrochemical industry. He helped the organization to reach to new heights in its initial stage of incorporation with the help of his substantial experiences and knowledge gained throughout his journey. He has vast knowledge of the business & related industries.
No. of Shares held as on March 31, 2025 including shareholding as a Beneficial Owner.	22,83,200	6,25,000	7,20,000
Terms & Conditions	Not Liable to Retire by rotation	Liable to retire by rotation	Not Liable to retire by rotation
Remuneration last Drawn	₹ 48.00 Lakhs Per Annum	₹ 2.25 Lakhs Per Month	₹ 2.25 Lakhs Per Month
Remuneration sought to be paid	₹ 75.00 Lakhs Per Annum	₹ 5.00 Lakhs Per Month	₹ 5.00 Lakhs Per Month
No. of meetings of the Board attended during	8 Meetings out of 8 Board Meetings	8 Meetings out of 8 Board Meetings	8 Meetings out of 8 Board Meetings

Name of Director	Mr. Narendra Singh Barhat	Mrs. Kusum Narendra Singh Barhat	Mr. Ketankumar Harkantbhai Joshi
the year.			
Date of Initial Appointment	17/03/2005	17/03/2005	27/08/2018
Date of Appointment (at current term)	26/09/2023	17/03/2005	20/03/2022
Directorships held in other companies (excluding foreign companies, Section 8 companies and Struck off Companies and our Company)	Nil	Nil	Nil
Memberships / Chairmanships of committees of other public companies	Nil	Nil	Nil
Inter-se Relationship with other Directors	He is a Husband of Mrs. Kusum Narendra Singh Barhat, Executive Director of the Company.	She is wife of Mr. Narendra Singh Barhat	No relationship with other Directors
Information as required pursuant to NSE Circular No. L1ST/COMP/14/2018-19 dated June 20, 2018	Mr. Narendra Singh Barhat is not debarred from holding the office of director pursuant to any SEBI order.	Mrs. Kusum Narendra Singh Barhat is not debarred from holding the office of director pursuant to any SEBI order.	Mr. Ketankumar Harkantbhai Joshi is not debarred from holding the office of director pursuant to any SEBI order.

THANKYOU FOR YOUR TRUST AND SUPPORT

REGISTERED OFFICE ADDRESS: E-24,25,26, G.I.D.C. ESTATE, MANJUSAR, TALUKA. SAVLI, DIST. VADODARA - 391775 GUJARAT, INDIA

WEBSITE: www.aristobiotech.com